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ABSTRACT
Alzheimer’s disease (AD) is the most common form of neurodegenerative disease.
Nationally, AD is the 6th leading cause of death and the only top 10 killer of Americans
that cannot be slowed, cured, or prevented. AD is characterized by the deposition of
extracellular plaques of aggregated amyloid-β protein (Aβ). Aβ originates from the
amyloid precursor protein (APP), a transmembrane protein that is cleaved to form a short
and inert protein fragment called Aβ. However, Aβ undergoes a nucleation process wherein
aggregates from soluble oligomers to insoluble fibrils are formed. While uncertainty
remains as to the exact mechanism, studies have associated Aβ aggregates with an increase
in reactive oxygen species (ROS), potentially explaining their toxicity. Unfortunately,
current AD treatments target disease symptoms and not the underlying cause.
Epidemiological studies have correlated particular diets with a reduced incidence
of AD. Most of these diets are rich in fruits and vegetables and previous studies have
identified many potential biochemical sources. Some, such as polyphenols, are of interest
because of both their ability to interfere with Aβ aggregation and their ability to attenuate
Aβ-induced intracellular ROS. Enhanced understanding of how biochemical can modulate
aggregation can lead to the development of new AD therapeutics. This study explores the
modulation of Aβ aggregation, either through 1) the use of small molecule modulators or
2) targeting a structural motif embedded in Aβ’s primary sequence.
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First, this study explored the mechanistic effects of both olive-derived
phenylethanoids and soy-derived isoflavones (SIFs) on Ab aggregation and toxicity. While
both groups effect aggregation, this did not attenuate toxicity. Next, antioxidant capacity
was investigated. Phenylethanoid and SIFs were good antioxidants. Further results
indicated that some SIFs increase activity of intracellular antioxidant enzyme catalase, an
enzyme responsible for hydrogen peroxide metabolizing. While no phenylethanoids had
an antioxidant effect on toxicity, one SIF, DEN, was able to modulate toxicity. Ultimately,
the strength of both groups was in their ability to act through both anti-aggregation and
antioxidant mechanisms simultaneously. Moreover, tyrosol, a phenylethanoid, and
genistein, a SIF, had a synergistic effects on Ab toxicity.
This study also explored ways in which aggregation could be altered using the Aβ
protein primary sequence. Amyloid proteins have a conserved glycine zipper motif
(GxxxG), which previous studies have shown to be important in oligomer formation and
cellular interaction. Results indicate that zipper motif extension increase aggregation
propensity and decrease aggregate size. Conversely, removal of a single zipper repeat has
a deleterious effect on aggregation, and when aggregates form, they are wispy aggregates
that lack many of the morphological features of traditional Aβ aggregates.
From modulation of aggregation propensity to targeting toxicity, there are many
viable routes to control Aβ. This study identified several promising ways to regulate Aβ
aggregation: phenylethanoids that successfully shift aggregate equilibrium but their
ultimate potential stems from their antioxidant capacity and dual action inhibition; SIFs
which modulate aggregation and ameliorate toxicity through an array of mechanisms; and,
finally, targeting the glycine zipper, which yielded dramatic effects on protein aggregation.
v
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE
1.1 Alzheimer’s Disease: An Overview
In 1906, Auguste Deter, a 51-year old German woman with rapid cognitive decline,
was admitted to a psychiatric hospital showing symptoms of dementia, hallucinations, and
delusions [1]. Upon her death, psychiatrist Alois Alzheimer discovered plaques, tangles,
and damage to her brain’s vasculature and diagnosed her with presenile dementia. More
than 100 years later, Alzheimer’s disease (AD), as it is now known, is the most common
form of neurodegenerative disease and, in the United States, the only top 10 cause of death
with no treatment, cure, or preventative [2]. While studies have established that it is a
combination of risk factors, such as age, genetics, and environment, that contribute to the
disease [3], one of the most important appears to be gender. AD has a clear gender bias; of
the 5.3M American AD patients over the age of 65, nearly 2/3 of them are women.
Incidence also increases with age; in Americans 70 and up, 16% of women have AD and
11% of men [2]. AD incidence rates, both nationally and globally, are expected to climb as
the population continues to grey, doubling roughly every 20 years.
AD treatment is often ineffective. The Food and Drug Administration (FDA) has
approved only 5 drugs for AD treatment: cholinesterase inhibitors donepezil and
rivastigmine for early stage AD; N-methyl D-aspartate (NMDA) antagonists memantine
and galantamine for late stage AD; and Namzaric®, which combines memantine and
donepezil [4]. However, these drugs treat the symptoms of the disease: acetylcholine is
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important for cognition and memory while NMDA antagonists work to stop glutamateinduced cell death. In addition to merely treating some AD symptoms, there are often
potent side effects associated with these drugs. Tacrine, a cholinesterase inhibitor once
approved for AD treatment was discontinued due to frequent severe liver damage [5]. In
addition to side effects and limits on efficacy, these treatment delay but do not stop disease
progression.
Current treatments and care, while only minimally effective, are also very costly.
In 2017, total healthcare costs for AD treatment and care are expected to exceed $250
billion. Over the next 30 years, as the number of AD patients is projected to grow to 13.8M,
costs are projected to exceed $1 trillion [2].
1.2 The Amyloid Cascade Hypothesis
While neuronal dysfunction and cell death are symptoms of AD, there are numerous
events preceding onset of the disease. The amyloid precursor protein (APP) is a
transmembrane glycoprotein found primarily in neurons. However, its function remains
poorly understood with theories ranging from transport [6] to adhesion [7] with little
consensus. Additionally, APP belongs to a family of evolutionarily conserved proteins that
appear in numerous species of mammals [8]. According to the sometimes controversial [9]
but widely accepted [10,11] theory of AD pathogenesis, the amyloid cascade hypothesis
[12], AD is caused by the accumulation of the 40-42 amino acid long protein amyloid-β
(Aβ) in the brain. In vivo, Aβ is produced from the sequential cleavage of APP. From
cerebrospinal fluid [13] to blood plasma [14], Aβ is also found in a variety of places in the
body.
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In vivo, APP undergoes sequential cleavage by a-secretase, b-secretase (BACE),
and g-secretase [15]. The formation of Aβ is heavily reliant on the sequence of cleavage.
a-secretase cleaves in the center of Aβ and produces non-amyloidogenic fragments. While
g-secretase cleaves at the Aβ C-terminus, BACE cleaves at the N-terminus and promotes
the formation of the toxic amyloidogenic protein associated with AD [5]. These secretases
are also the target of numerous familial mutations that can impact both the amount of
protein produced and the severity of the disease.
1.3 Aβ Aggregation
While monomeric Aβ is inert and non-toxic, aggregated Aβ is associated with
toxicity. Although the trigger for aggregation remains elusive, physical trauma such as
traumatic brain injury (TBI) [16,17] and environmental factors [18] have been
hypothesized to play a role. Once triggered, Aβ aggregates in a nucleation dependent
pathway [19]. After the formation of early aggregates known as oligomers, aggregates
rapidly coalesce to form insoluble fibrils and, eventually, these fibrils deposit as plaques
frequently found in AD brain [20–22]. This process typically follows a sigmoidal growth
curve with a lag, growth, and plateau phase as illustrated in Figure 1.1.
As Aβ aggregates, it develops a characteristic β-sheet structure [23]. While the
exact reasoning for this remains elusive, it is a common trait amongst amyloid proteins
such as amylin (Type II Diabetes) or a-synuclein (Parkinson’s disease) [24]. It is theorized
that the β-sheets are stabilized through p-p stacking of the aromatic phenylalanine
residues [25].
In vivo, Aβ1-42 exists in a roughly 1:10 ratio with Aβ1-40 [26,27]. While greatly
outnumbered by its smaller isoform, it has consistently proven to be the most toxic
3

species [23]. Additionally, Aβ1-42 has an increased propensity to aggregate due to its
increased hydrophobicity. Aggregated Aβ1-40 and Aβ1-42 also deposit in different regions in
vivo: Aβ1-40 is typically found in vascular deposits while Aβ1-42 typically deposits in the
brain [28,29].
1.4 Mechanisms of Toxicity
Many characteristics, such as the size or conformation, of toxic Aβ aggregates
remain unclear [30]. Previously, fibrils, the large aggregates predominantly found in
plaques, were thought to be the most toxic species. Recent studies, however, have shown
that early aggregates like oligomers play an important role [31–33].
The mechanism behind oligomer toxicity likely involves oxidative processes such
as reactive oxygen species (ROS) [5]. ROS, if left unchecked, can damage a myriad of
intracellular mechanisms and components. Some studies have shown that, during the
aggregation process, Aβ spontaneously forms peroxide radicals, a form of ROS [34,35].
ROS also serves as a positive feedback loop. Studies have shown that the release of ROS
as the result of mitochondrial dysfunction can actually stimulate Aβ aggregation [36].
1.5 Familial Alzheimer’s Disease
AD is generally divided into two forms: early-onset and late-onset [37]. While lateonset AD accounts for roughly 95% of AD cases and is associated with normal aging,
early-onset can frequently be attributed to inherited mutations [38]. These mutations can
affect a range of molecular targets such as the ApoE gene, a protein involved in signaling
and binding, or the presenilin family of genes, which code for l-secretase. These mutations
can range of effects from beneficial changes such as increased susceptibility to l-secretase
cleavage [39], mutations within the APP sequence that increases secretase affinity, or even
4

within the Aβ sequence itself. Figure 1.2 illustrates commonly identified familial mutations
inside the Aβ primary sequence. While some mutations have an effect on total Aβ
production (Leuven, Swedish) others alter aggregation propensity (Iowa, Arctic, Dutch,
English) and some do both (French, German, Austrian) [31,40].
1.6 Next Generation Therapies
With the dearth of effective AD treatments, studies are ongoing for new and
innovative alternatives. Some recent attention for AD treatment has centered around socalled nutraceuticals: naturally occurring dietary compounds and food additives that
provide extra health benefits. While some therapeutics have shown the ability to interfere
with p-p stacking and break up β-sheet structure [41–45], polyphenols, dietary components
commonly found in fruits and vegetables, are of particular interest. Numerous studies have
proven their ability to attenuate Aβ-associated toxicity or alter the biophysical properties
of aggregates [46–52], likely as a result of their typically hydrophobic and hydroxylated
structure.
But their appeal does not stop at aggregation. Many of these compounds, such as
polyphenols, are known for being potent antioxidants. As such, studies additionally
attributed their success to their antioxidant capacity, counteracting toxic free radicals as
they interfere with the aggregation process [53,54]. Additionally, previous work has
specifically found that antioxidant potential can be more powerful and beneficial than antiaggregation effects [46].
Other treatments are seeking to use the protein inspired design to alter
aggregation [44,55]. Some of the most promising studies are creating monoclonal Aβ
antibodies and using these to develop therapies while other are using the core Aβ sequence
5

and creating inhibitors. Others still are taking a repeating glycine zippper structural motif
embedded within APP and creating novel inhibitors [56].
1.7 Study Overview
This study investigates ways to modify Aβ aggregation through either the use of
small molecule inhibitors such as 1) phenylethanoids derived from olives, 2) isoflavones
from soybeans, or 3) via rationally designed Aβ sequence mutations. Aggregates were
characterized for a variety of biophysical features ranging from morphology to toxicity.
These studies comprise the three aims of this work and are described in more detail below.
1.7.1 Phenylethanoids modulate aggregation and oligomer toxicity in Alzheimer’s
disease
The first aim of this work is to test the hypothesis that phenylethanoids can alter
the course of Aβ pathogenesis. This aim biophysically characterized the interaction
between phenylethanoids and Aβ. Using a monomer aggregation assay and transmission
electron microscopy, phenylethanoids were assessed for their effect on the entire
aggregation pathway and aggregate morphology. Oligomers formed in the presence of
phenylethanoids were used to both characterize the size and distribution of oligomers, but
also their effect on caspase activation in neuroblastoma cells. Next, the antioxidant capacity
of phenylethanoids was assessed and subsequently toxicity was tested using pre-formed
oligomers and neuroblastoma cells. This study culminates in an assessment of the
synergistic potential of phenylethanoids.
1.7.2 Soy isoflavones attenuate Aβ toxicity through multiple mechanisms and pathways
The second aim of this work tests the hypothesis that soy isoflavones (SIFs) can
modulate Aβ aggregation and attenuate toxicity. SIFs were assessed for their ability to act
6

simultaneously through anti-aggregation pathways and antioxidant pathways. Next, to
ascertain the exact mechanism for each SIF, the anti-aggregation effects were explored for
their ability to change monomer aggregation using a fluorescent assay, alter morphology
using electron microscopy, change oligomer size and distribution using SDS-PAGE with
Western blot, or, finally, to alter oligomer conformation using a hydrophobic dye. Finally,
the effect of SIF anti-aggregation on caspase activation was assessed. Antioxidant effects
of SIFs were assessed using three methods. First, the total antioxidant capacity of each SIF
was assessed. Secondly, their ability to increase catalase activity, a hydrogen peroxide
metabolizing enzyme, was determined as was the ability of SIFs to affect caspase activation
through antioxidant processes. Finally, the mechanism of action for each SIF was
established.
1.7.3 Changes to the Aβ glycine structural motif effect aggregation
The third and final aim of this work tests the theory that increasing the periodicity
of glycine in Aβ increases the aggregation rate. Embedded within APP is a series of
repeated glycine residues that create a glycine zipper structural motif. Four mutations were
selected for their ability to either increase or decrease the zipper and for continuing this as
either a direct extension of the motif or shifted by one amino acid. Additionally, two
extensions were selected for their similarities to two epidemiologically identified familial
mutations. Mutants were initially assessed for their ability to modulate the entire
aggregation pathway and their effect on aggregation kinetics were assessed. These
aggregates were then collected and assessed for their morphology using electron
microscopy, a change in aggregate conformation using a hydrophobicity assay, or change
aggregate size via light scattering.
7
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Figure 1.1. Aβ aggregation pathway. Aβ aggregates in a very distinctive pathway
consisting of three distinct phases: lag phase where monomer begins to coalesce and form
nuclei, a rapid growth phase where soluble species are rapidly growing, and an equilibrium
phase where all species, including fibrils, exist in a metastable equilibrium.
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G (Flemish) N (Iowa)
1

DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV 40
R (English)

G (Arctic)
Q (Dutch)
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K (Leuven)

Figure 1.2. Common familial Aβ mutations. Aβ mutations have been identified in a
numberZVof
commonly
occurring genetic cases of AD. The most common target is the3 region
Pre-Defense
8/29/17
of the β-hairpin turn. Adapted from Benilova et. al [31].

9

CHAPTER 2
MATERIALS AND METHODS
2.01 Materials
Aggregation modulators were purchased from Indofine Chemical Company
(Hillsborough, NJ). Lyophilized Aβ1-40 and Aβ1-42 were obtained from Peptide 2.0
(Chantilly, VA) and AnaSpec, Inc. (San Jose, CA), respectively. 1,1,1,3,3,3-Hexafluoro2-propanol (HFIP) and thioflavin T were obtained from Sigma (St. Louis, MO). Dimethyl
sulfoxide (DMSO) was purchased from EMD Biosciences (San Diego, CA). Uranyl acetate
was obtained from Electron Microscopy Sciences (Hatfield, PA). Tricine and Lamelli
sample buffers, gels and standards for electrophoretic separations, and membranes for
protein transfer were purchased from Bio-Rad (Hercules, CA). Primary antibody 6E10 was
purchased from Biolegend (San Diego, CA). Superdex 75 prep grade resin and secondary
antibody ECL Mouse IgG, HRP-linked were purchased from GE Healthcare Life Sciences
(Pittsburg, PA). Pierce™ SuperSignal™ West Pico PLUS chemiluminescent substrate was
obtained from Thermo Scientific (Waltham, MA). 8-anilino-1-naphthalenesulphonic acid
(ANS) was obtained from Research Organics (Cleveland, OH). Recombinant human tumor
necrosis factor-α (TNF-α) was purchased from Promega (Madison, WI). Cell culture media
components were obtained from MilliporeSIgma (St. Louis, MO). All other chemicals
were purchased from VWR (Radnor, PA).
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2.02 Preparation of Aβ1-40 Monomer
Lyophilized Aβ1-40 was stored desiccated at -20°C prior to use and was prepared
for experimentation as previously described [57]. In brief, the peptide was reconstituted in
50 mM NaOH (2 mg/mL) and purified utilizing an AKTA FPLC (GE Healthcare,
Piscataway, NJ) and a Superdex 75 HR 10/300 column (GE Healthcare) pretreated with
bovine serum albumin (0.5 mg) as shown in Figure 2.1. Fractions of isolated monomer
were eluted in 40 mM Tris-HCl (pH 8.0), and protein concentration was determined using
a calculated extinction coefficient of 1450 M-1 cm-1 at 280 nm [34]. Purified monomer was
stored for up to 2 days at 4°C before use.
2.03 Aβ1-40 Monomer Aggregation
The formation of Aβ aggregates was monitored within reactions containing 5 µM
SEC-purified Aβ1-40 monomer and 0 µM (control) or 50 µM aggregation modulator.
Reactions were prepared in 40 mM Tris-HCl (pH 8.0) containing 18.75 mM NaCl, 10 µM
thioflavin T, and 1% (v/v) DMSO. Inclusion of thioflavin T, a fluorescent dye that
specifically binds amyloid β-structure to yield a shifted, enhanced fluorescence, enabled in
situ detection of aggregates. Reaction mixtures were loaded in triplicate onto a 96-well
plate and covered with crystal clear sealing tape (Hampton Research, Aliso Viejo, CA) to
prevent evaporation. To promote aggregation, reactions were agitated at 20°C on a Synergy
2 Multi-Mode microplate reader (BioTek, Winooski, VT). Thioflavin T fluorescence
measurements were acquired every 15 min (ex/em 440±30/485±20 nm) until plateau
fluorescence was observed for all samples.
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2.04 Modeling of Amyloid-β Aggregation
Using GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA) software,
aggregation data exhibiting a standard three-phase growth (Figure 2.2A) were fit using
equation 1, a typical sigmoidal growth curve [19,58]:
#

y = $%&'((*'+,..)

(1)

where A is the extent of aggregation at equilibrium, k is the rate of aggregate formation
during the growth phase, and t0.5 is the half-time to equilibrium. Using a least square
(ordinary) fit and program identified initial values, the model was iterated until
convergence. The lag time to aggregate formation was calculated from model parameters
t0.5 and k as:
$

t 234 = t 5.6 − 8∙:

(2)

Times and fluorescence values were normalized based on the calculated tlag and A
for the control, respectively. Therefore, a value of 1 for either tlag or A represents no change
from the control. Values less than 1 indicate an attenuation of the lag time and a reduction
in the extent of aggregation, while values greater than 1 represent an extension of the lag
time and an increase in the extent of aggregation.
To evaluate the kinetics for more advanced aggregation curves that have both a
growth and a decay phase (Figure 2.2B), a new model was developed based on the
foundational works of Fernandes and Caglar [59,60]:
y=;

y<=>,>@ABCD
y<=>,LMKNO

𝑓𝑜𝑟 𝑥 < 𝑡K@=C
𝑓𝑜𝑟 𝑥 > 𝑡K@=C

(3)

where
#

y<=>,>@ABCD = $%&'((*'+,..)
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(4)

and
y<=>,LMKNO =

#
$%&'((*'+,..)

+

RS#
$%&'T(*'+U..)

(5)

While A, k and t0.5 represent the same features as described above, B represents the change
in fluorescence after equilibrium is reached, c is the decay phase rate constant, and tcrit
represents the time when maximum fluorescence is reached and the transition from primary
equilibrium to decay occurs. Using the robust fit method and program identified initial
values for A, k, t0.5, B, c, t1.5, and tcrit the model were used to iterate until convergence.
Model values were constrained such that all values except B were positive and 0 < t0.5 < 2.
tlag was calculated using equation 2 above while secondary lag was calculated with
equation 6:
t &VW = t $.6 −

$
8∙K

(6)

where tend represents the period in primary equilibrium where the decay phase begins.
2.05 Transmission Electron Microscopy
At terminal time points of aggregation reactions, samples were loaded onto
Formvar/Carbon film 300 mesh copper grids (Electron Microscopy Sciences, Hatfield, PA)
as previously described [46]. Briefly, samples were added to grids and allowed to adsorb
for 5 min, excess solution was wicked away, and grids were air dried for 5 min. Loading
was repeated 5 times. Samples were allowed to air dry thoroughly (15 min) before staining
with 2% uranyl acetate (8 min). Excess stain was wicked away, and the grid was air dried
overnight. Images were acquired using a JEM 1400 Plus Transmission Electron
Microscope (120kV).
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2.06 Aβ1-42 Oligomerization
Oligomers were created as previously described [46]. Briefly, Aβ1-42 was dissolved
in HFIP at -20°C for 1 h and aliquoted. HFIP was allowed to evaporate overnight and dried
protein films were stored in desiccant at -80°C until use. Dried Aβ1-42 films were
reconstituted in DMSO at a concentration of 5 mM. Protein was then further diluted with
DMSO containing 10-fold molar excess of phenylethanoid or an equivalent volume of
DMSO alone (control). Oligomerization was initiated via dilution in phosphate buffer
(pH 7.4) containing 1 µM NaCl for final concentrations of 15 µM Aβ, 150 µM aggregation
modulator, and 2.5% (v/v) DMSO. After 30 min, oligomerization reactions were either
stabilized by the addition of 0.1% Tween 20 or else used immediately.
2.07 Aβ1-42 Oligomer Resolution via SDS PAGE with Western blot
As previously described, SDS PAGE with Western blot was used to resolve and
quantify monomer and oligomeric aggregate species [46]. To assess monomer, trimer, and
tetramer species, oligomerization end products were mixed 1:2 with Tricine sample buffer
and loaded onto a 16.5% Mini-PROTEAN® Tris-Tricine Gel alongside Precision Plus
Protein™ Dual Xtra Standard. Proteins were separated by electrophoresis (100 V) in a
Mini-PROTEAN Tetra Cell (Bio-Rad). Following separation, proteins were transferred
onto a 0.2 µm nitrocellulose membrane using a Trans-Blot® SD Semi-Dry Transfer Cell
(Bio-Rad) (13 V, 12 min).
To assess larger oligomers, oligomerization end products were mixed 1:1 with
Lamelli buffer and loaded onto a 4-20% Mini-PROTEAN® TGX™ precast gel alongside
Precision Plus Protein™ WesternC™ Standard. Electrophoretic separation in a Mini-
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PROTEAN Tetra Cell occurred at 120 V before transfer (15 V, 15 min) onto 0.2 µm
nitrocellulose membrane.
Nitrocellulose membranes with transferred oligomers were blocked overnight at
4°C with 5% non-fat dry milk in 12 mM phosphate buffer (pH 7.4) containing 0.1% Tween20. Membranes were then probed with 6E10 primary antibody (1:2,000), HRP-conjugated
anti mouse secondary antibody (1:2,000), and for membranes with WesternC™ standard,
Precision Protein StrepTactin-HRP conjugate (1:1,875). Membranes were placed in
chemiluminescence enhancing solution for 2 min, and images were acquired using a BioRad ChemiDocTM XRS+ (Bio-Rad) imaging system. Densiometric analysis of aggregate
species was conducted using Image Lab 5.2.1 (Bio-Rad) software. For larger oligomers,
the presented intensity was determined within regions from 25–100 kDa or 100–250 kDa.
For monomer, trimer, and tetramer species, individual band intensity was evaluated.
Intensity results are expressed as a fraction of the control.
2.08 Assessment of Aβ1-42 Oligomer Conformation using ANS Spectroscopy
8-Anilino-1-naphthalenesulfonic acid (ANS) was resuspended at 50 mM in DMSO
and stored at 4°C until use. Immediately prior to use, ANS was diluted to 50 µM using
12 mM phosphate buffer (pH 7.4). This sub-stock was then used to dilute oligomers formed
in either the presence or absence (control) of aggregation modulator to a final concentration
of 1 µM Aβ, 10 µM aggregation modulator, and 50 µM ANS. Sample fluorescence was
measured using a LS-45 luminescence spectrometer (Perkin–Elmer, Waltham, MA)
(excitation = 350 nm, emission = 400-600 nm). Area under the curve (AUC) was then
calculated by blank subtracting and integrating from 450-550 nm.
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2.09 Cell Culture Maintenance
Human neuroblastoma SH-SH5Y cells (American Type Culture Collection,
Manassas, VA) were maintained in a 1:1 mixture of Dulbecco’s Modified Eagle’s Medium
and Nutrient Mixture F-12 Ham Kaighn’s Modification Medium (DMEM/F12K)
supplemented with fetal bovine serum (FBS) (10%), penicillin (100 units/mL), and
streptomycin (100 µg/mL). Media was changed every 48-72 h. Upon reaching 70%
confluency, cells were seeded for experimentation onto No. 1.5 glass coverslips, 22 x 20
mm (MatTek, Ashland, MA) at a concentration of 1.5 x 106 cells/well. All cultures were
maintained at 37°C in a humid atmosphere with 5% CO2.
2.10 Cell Treatments
Cellular treatments were applied 24 h following seeding onto coverslips. To
examine the biological effect of modulator-induced changes in oligomerization, oligomers
were formed in the presence of a 10-fold excess of phenylethanoid and added to cells at a
final concentration of 10 nM Aβ1-42 and 100 nM aggregation modulator. To examine effects
on intracellular antioxidant-associated processes, cells were treated simultaneously with a
high concentration of modulator and oligomers formed in the absence of the modulator,
using final concentrations of 10,000 nM modulator and 10 nM Aβ1-42. Finally, to examine
the ability of anti-aggregation and intracellular antioxidant-associated processes to act
simultaneously, cells were treated simultaneously with a high concentration of modulator
and oligomers formed in the presence of modulator, using final concentrations of 10,000
nM modulator and 10 nM Aβ1-42. All treatments were diluted into DMEM/F12K containing
1% FBS. Treatments prepared with buffer equivalent served as a negative control; cells
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treated with 1.5 U TNF-α or with oligomers formed in the absence of aggregation
modulators served as positive controls.
2.11 Assessment of Caspase Activation
The Image-iT® LIVE Green Poly Caspases Detection Kit (Life Technologies), as
previously described [46], was used to determine the effect of phenylethanoids on Aβinduced activation of caspases, including caspase-1, caspase-3, caspase-4, caspase-5,
caspase-6, caspase-7, caspase-8, and caspase-9, as an indicator of apoptosis. Following
24 h cellular treatments (37°C, 5% CO2) described above, media was removed, and cells
were washed using 1% FBS, phenol red free media. Cells were then incubated (1 h, 37°C,
5% CO2) with 200 µL of 1X fluorescent inhibitor of caspases (FLICA™) reagent prepared
according to the kit. Cells were rinsed and incubated for 10 min with 0.1 mM Hoechst 3342
(37°C, 5% CO2) in 1% FBS, phenol red free media. Cells were then washed before fixation
using the included apoptosis fixative solution. Cells were mounted onto glass slides and
imaged within 24 h using a Nikon Eclipse 80i fluorescent microscope (Melville, NY)
equipped with a 40x objective, Nikon NIS-Elements 3.0.
Five images were acquired for each slide with channels acquired for both Hoechst
and FLICA™. As previously reported, results were quantified using a custom MATLAB
(MathWorks, Natick, MA) function (Appendix A) to determine the percentage of caspase
active cells in each image. Results are reported as the percentage of caspase active cells
normalized to the control. A value of 1 represents no change in caspase activity as
compared to treatment with Aβ oligomers alone, while a value of 0 represents the complete
elimination of Aβ-induced caspase activity.
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2.12 Oxygen Radical Antioxidant Capacity
To measure antioxidant capacity of phenylethanoids, the OxiSelectTM Oxygen
Radical Antioxidant Capacity (ORAC) assay (Cell BioLabs, San Diego, CA) was
employed as previously described [46]. Samples were freshly dissolved in DMSO and
diluted into 75 mM potassium phosphate (pH 7.0) for final concentrations of 1 µM and
1% (v/v) DMSO. Trolox, a Vitamin E analog, served as the antioxidant standard. Samples,
prepared in triplicate, or varying concentrations of Trolox (0 – 15 µM) were combined with
a 6-fold (v/v) excess of fluorescein in a black-walled 96-well plate and incubated (37°C,
30 min). Reactions were then mixed with 295 µM free radical initiator (2,2’-azobis(2methylpropionamidine) hydrochloride). To observe quenching of fluorescein by the
resulting free radicals, fluorescein fluorescence (ex/em 485 ± 20/528 ± 20 nm) was
measured at 1 min intervals for a period of 60 min using a Synergy 2 Multi-Mode
microplate reader. The area under the fluorescence vs. time curve (AUC) was calculated
and blank (0 µM Trolox) subtracted. Trolox samples were used to construct a standard
curve of AUC vs. concentration, which was applied to convert phenylethanoid AUC to an
ORAC value, or the equivalent Trolox concentration per molar concentration of sample.
2.13 Total Antioxidant Capacity
To measure the antioxidant capacity of SIFs, the QuantiChrom™ Antioxidant
Assay Kit (BioAssay Systems, Hayward, CA) was used. Trolox standards (0-1000 µM)
and SIFs (1.67 µM) were loaded in triplicate onto a clear bottom 96-well plate, diluted
using Working Reagent, a solution of buffer with Cu2+ which can be reduced by
antioxidants, and incubated (room temperature, 10 min). Absorbance was measured at
570 nm on a Spectramax 190 Microplate Reader (Molecular Devices, Sunnyvale, CA) and
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blank (0 µM Trolox) subtracted. TAC values were calculated by determining from the
standard curve the equivalent Trolox concentration for each measured SIF absorbance.
Values are reported as the equivalent Trolox concentration.
2.14 Catalase Activity Assay
The effect of SIFs on the activity of hydrogen peroxide reducing enzyme catalase
was assessed using the Amplex™ Red Catalase Kit (Thermo Fisher, Waltham, MA).
Catalase standards (0-250 mU/mL) were prepared in 0.1 M Tris-HCl. In parallel, samples
containing 800 µM SIF were incubated with 125 mU/mL catalase (room temperature,
5 mins). Samples and standards were incubated (room temperature, 30 min) with 20 µM
H2O2 in a clear bottom 96-well plate. Samples and standards were diluted in half with
50 µM Amplex™ Red and 0.5 U HRP and incubated (37°C, 30 min). Absorbance
(560 nm) was blank subtracted (0 mU/mL catalase) to give the net absorbance. Using the
catalase standard curve, net absorbance values for SIFs were converted into an equivalent
catalase concentration and normalized to catalase alone (y=1).
2.14 Dynamic Light Scattering
To assess relative aggregate size, 10 µL of samples were loaded into a quartz
cuvette and placed in a DynaPro MSX DLS instrument (Wyatt Technology Corporation,
Santa Barbara, CA). Dynamic light scattering (DLS) allows for the nondestructive
measurement of samples using correlative light scattering techniques and allows for
detection of particles from 1-1000 nm. Instrument parameters were set to 50 acquisitions
and values were averaged to obtain a hydrodynamic radii (RH). The average of these
acquisitions was reported and represents the sample RH.
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2.15 Statistical Analysis
Data were Grubbs’ tested for outliers and are presented as the mean ± SEM. Using
Minitab Express 1.5.1 (State College, PA), data were evaluated for normality and equal
variances using the Anderson-Darling and Bartlett methods, respectively. Data passing
both tests were analyzed using parametric methods. One-way analysis of variance
(ANOVA) with Dunnett's test was employed to identify means significantly different from
the control, while an unpaired two-tailed t-test was performed for comparisons between
compounds. Data violating the underlying ANOVA assumptions were subjected to
Kruskal-Wallis and Mann-Whitney tests to identify significance. For all methods,
significance is defined as p < 0.05.
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Figure 2.1. Purification profile of Aβ1-40 using size exclusion chromatography. Aβ
monomer was denatured in NaOH and loaded onto an AKTA FPLC for size exclusion
chromatography using Superdex 75 prep grade resin. Pre-formed aggregates are too large
to enter the resin and elute early in the void volume, Monomer elutes second in the region
identified with the blue box. Finally, any peptide fragments not removed by the
manufacturer elute after the monomer, typically in the solvent volume.
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Figure 2.2. Example aggregation curves. Monomer were aggregated in the presence of
salt and a 2-fold excess of Thioflavin T. Sample fluorescence was measured every 15
minutes and reported. While WT Aβ1-40 monomer aggregated in a traditional three phase
growth curve (Panel A), glycine zipper mutants had 5 phase curves (Panel B).
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CHAPTER 3
OLIVE OIL PHENYLETHANOIDS ATTENUATE ALZHEIMER’S
AMYLOID-β OLIGOMERS THROUGH MULTIPLE MECHANISMS
3.1 Introduction
An association between adherence to the Mediterranean Diet (MeDi) and a lowered
risk for Alzheimer’s disease (AD) has been identified via epidemiological evidence [61–
64]. AD brain is characterized by parenchymal deposits of insoluble plaques containing
aggregated amyloid-β protein (Aβ). Ab aggregation occurs via a nucleation dependent
pathway from non-toxic monomer to β-sheet rich fibrils that comprise plaques. Prior
studies have highlighted the particular capacity of MeDi staple olive oil to attenuate AD
pathology in mouse models, exemplified by a reduction in Aβ plaque load and an
improvement in cognitive function [65,66]. Among olive oil’s chemical constituents,
phenylethanoids have shown promise in disrupting biochemical interactions associated
with a variety of medical conditions [67–70], including neurodegenerative diseases such
as AD [48,71–76].
Of interest in AD, phenylethanoids oleuropein aglycone and oleocanthal attenuate
Aβ toxicity by targeting Ab aggregates [48,75,76]. Although fibrillar Aβ plaques are a
hallmark of the disease, oligomers, transient intermediates on the Aβ aggregation pathway,
are acutely neurotoxic [10,23,77]. Among other detrimental effects of oligomers, the
folding process creates a spontaneous burst of hydrogen peroxide [34,78]. Failure to
remove or otherwise neutralize the resultant reactive oxygen species (ROS) can further
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promote the Aβ aggregation process [36] or initiate the formation of toxic free radicals that
induce apoptosis [35]. Targeting of the oligomerization process itself and counteracting
Aβ-induced ROS via antioxidant capabilities present two potential mechanisms for
phenylethanoids to attenuate AD pathogenesis.
Some dietary components exhibit the ability to dually regulate Ab aggregation and
mediate ROS-induced toxicity [46,47,52,79]. This ability is frequently attributed to two
structural characteristics: the phenol ring and its hydroxyl functionalization. Both features
are present in phenylethanoids. One hypothesis suggests that chemical compounds with
hydroxylated phenol rings have the capacity to interfere with the π-π stacking necessary
for formation and stabilization of Aβ aggregates [25]. Additionally, phenolic compounds
are typically potent antioxidants capable of counteracting ROS [51,52,80].
This study focuses on the three most abundant phenylethanoids in olive oil:
oleuropein (OLE), hydroxytyrosol (TOH), and tyrosol (TYR) (Figure 1) [81]. During olive
oil production, naturally occurring OLE is broken down into TOH by the crushing process
and further degraded into TYR by the aging process. Previous studies have examined the
effect of isolated OLE and metabolites on various aggregate species [48,66,71,76].
However, these studies have limited the scope of their investigation to a singular
phenylethanoid or mechanism. In this study, OLE and its metabolites are explored for both
their anti-aggregation and antioxidant capabilities. Results demonstrate that all three
compounds, OLE, TOH, and TYR, shifted the equilibrium from small oligomers towards
larger aggregates, and OLE additionally increased the extent of aggregation; however,
these changes did not result in reduced oligomer toxicity. These compounds are all also
capable antioxidants, and, through this mechanism, they modulated oligomer toxicity in a
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manner proportional to their antioxidant capacity. Notably, these compounds exhibit their
most prominent effect toward combating oligomer toxicity when shifted aggregation
equilibrium and antioxidant capabilities were allowed to act in tandem, demonstrating their
potential in AD treatment as multi-target small molecule natural therapeutics.
3.2 Materials and Methods
3.2.1 Phenylethanoid Preparation
Phenylethanoids OLE, TOH, and TYR were purchased from Indofine Chemical
Company (Hillsborough, NJ). Prior to use, 10 mM phenylethanoid were freshly dissolved
in DMSO.
3.2.3 Aβ1-40 Monomer Aggregation
SEC-purified Aβ1-40 monomer (Section 2.02) was used to determine the effects of
phenylethanoids on aggregation. 5 µM monomer was aggregated in the absence (control)
or presence of 50 µM of OLE, TOH, or TYR and 10 µM Thioflavin T as described in
Section 2.03.
3.2.4 Transmission Electron Microscopy
Transmission electron microscopy (TEM) was used to assess changes in aggregate
morphology. The end product of Aβ monomer aggregation (Section 3.3.3) were loaded
onto TEM grids, prepared via negative staining with uranyl acetate, and imaged as
described in Section 2.06.
3.2.5 Three-Stage Kinetic Modeling of Amyloid-β Aggregation
Aggregation data (Section 3.2.3) were fit to a three-phase growth curve as described
in Section 2.04. Data for the control (0 µM phenylethanoid) were fit initially and all data
points were normalized to the control amplitude and control lag time. Normalized data sets
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were then fit. Therefore, a value of 1 for either tlag or A represents no change from the
control. Values less than 1 indicate an attenuation of the lag time or a reduction in the extent
of aggregation, while values greater than 1 represent an extension of the lag time or an
increase in the extent of aggregation.
3.2.6 Oligomer Resolution via SDS-PAGE with Western blot
Aβ1-42 oligomers were created in the presence of a 10-fold excess of either OLE,
TOH, or TYR as described in Section 2.06 and stabilized with 0.1% Tween-80. Oligomers,
as explained in Section 2.07, were electrophoretically resolved using SDS-PAGE and
Western blot. Densiometric analysis of aggregate species was conducted and intensity was
determined for monomer, trimer, and tetramer species a well as regions from 25–100 kDa
or 100–250 kDa. Intensity results are expressed as a fraction of the control (oligomers
formed in the absence of phenylethanoid).
3.2.7 Cell Treatments
SH-SY5Y human neuroblastoma cells were maintained and seeded as described
(Section 2.09). 24 h after seeding, cells were treated with Aβ oligomers in one of three
ways described in Section 2.10: either 1) 10 nM Aβ1-42 oligomers that were formed in the
presence of 100 nM phenylethanoid, 2) 10,000 nM phenylethanoid and 10 nM Aβ1-42
oligomer formed in the absence of phenylethanoid, or 3) 10,000 nM phenylethanoid and
10 nM Aβ1-42 formed in the presence of 100 nM phenylethanoid. Media containing 1.5 U
TNF-a served as the positive control.
3.2.8 Assessment of Caspase Activation
Treated cells (Section 3.2.7) were stained with the Image-iT® LIVE Green Poly
Caspases Detection Kit (Life Technologies) as described in Section 2.11. Coverslips were
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mounted onto glass slides and imaged within 24 h using a Nikon Eclipse Ti-E fluorescent
microscope (Melville, NY) and Nikon NIS-Elements 3.0. Images were acquired in the blue
(Hoechst) and green (FLICA™). Results were quantified using a custom MATLAB code
which can be found in Appendix B and Appendix C. Results were reported as percentage
of caspase active cells for each sample relative to the control.
3.2.9 Phenylethanoid Antioxidant Capacity
As described in Section 2.12, the ORAC value of phenylethanoids was determined
using the OxiSelectTM Oxygen Radical Antioxidant Capacity assay. Trolox, a Vitamin E
analog, served as the standard. Fluorescence was measured at until it returned to the
baseline. The blank subtracted area under the fluorescence vs. time curve (AUC) was
calculated and Trolox samples were used to construct a standard curve of AUC vs.
concentration. Using this, phenylethanoid AUC was converted to an ORAC value (the
equivalent Trolox concentration per molar concentration of phenylethanoid).
3.3 Results
3.3.1 Oleuropein Target Early Stages of Aggregation and Promote the Formation of
Aβ1-40 Aggregates
To examine the effect of phenylethanoids upon Aβ1-40 aggregation, SEC-purified
monomer was aggregated in the presence of a 10-fold excess of phenylethanoid compound.
Aggregation was monitored via inclusion of a 2-fold excess of thioflavin T, which displays
enhanced fluorescence in the presence of amyloid β-sheet structure. As shown in
Figure 3.2A, aggregation of Ab1-40 monomer exhibits a lag phase, followed by a period of
exponential growth, and concluding in a plateau as equilibrium is reached. To determine
the lag time to aggregate formation (tlag), the extent of aggregation at equilibrium (A), and
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the rate of aggregate formation during the growth phase (k), aggregation data were fit to a
three-stage kinetic model (Eqs. 1 and 2). While the presence of all three phenylethanoids
led to some reduction in the lag time, only OLE significantly impacts the lag phase of
aggregation (Figure 3.2A; Table 3.1). OLE also exhibits the most pronounced effect on the
amplitude of the equilibrium plateau, increasing the extent of aggregation at equilibrium
by 2-fold. All three phenylethanoids promote some increase in the rate of aggregate
formation as compared to the control, but this effect fails to reach significance.
Table 3.1. Effect of phenylethanoids on Aβ monomer aggregation a,b
tlag

A

k

CONT

1.00 ± 0.00

1.00 ± 0.00

12.30 ± 4.00

OLE

0.20 ± 0.04*

1.99 ± 0.23*

16.87 ± 6.20

TOH

0.62 ± 0.26

0.96 ± 0.18

28.44 ± 3.19

TYR

0.58 ± 0.25

1.13 ± 0.26

31.57 ± 13.19

*p<0.05, compared to control.
a
Monomer aggregation experiments were performed as in Figure 3.2A.
b
Parameters were derived from fitting normalized thioflavin T fluorescence
vs. time data to a three-stage kinetic model (Eqs. 1 and 2; Figure 3.2A,
solid lines) and are expressed as mean ± SEM, n = 4–5.
To determine whether observed changes in aggregation kinetics were accompanied
by alterations in fibril morphology, at terminal aggregation time points, samples were
gridded and stained for transmission electon microscopy. Aggregation performed in the
absence of phenylethanoids led to the formation of a network of filamentous structures
exhibiting both single strands and bundled filaments. This morphology was unchanged by
the presence of any phenylethanoid (Figure 3.2B). Together, these results demonstrate that
phenylethanoid OLE targets the earliest aggregate species and can increase quantity of
aggregates formed without changing aggregate morphology.
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3.3.2 Phenylethanoids Reduce the Quantity of Aβ1-42 Oligomers Formed
To further explore the observed effect of phenylethanoids on early stages of the
aggregation process, the ability of these compounds to alter oligomerization of Ab1-42 was
evaluated. Here, the longer isoform of Ab, which forms stable oligomers, was employed.
Aβ1-42 oligomerization was initiated via the dilution of DMSO-solubilized monomer into
aqueous buffer. Oligomers were formed in the presence and absence of phenylethanoids,
and resulting oligomer size and quantity were assessed using SDS-PAGE with Western
blotting to resolve oligomeric species.
Separations performed using a 16.5% Tris-Tricine gel (Figure 3.3B) demonstrate
that the presence of a 10-fold molar excess of each phenylethanoid reduces the quantity of
trimeric and tetrameric oligomer (Figure 3.3D). In addition, a reduction in monomeric
protein is observed (Figure 3.3E). The most pronounced reduction in small oligomer
species occurs when oligomers are formed in the presence of TYR, which reduces trimer
and tetramer by greater than 70% compared to the control (Figure 3.3D). In contrast,
separations performed using a 4-20% Tris-glycine gel (Figure 3.3A) reveal that
phenylethanoids exert a less pronounced effect on the formation of higher order oligomer
species, with a significant reduction in 100-250 kDa oligomers observed only in the
presence of TOH (Figure 3.3C). Together, these results establish the ability of
phenylethanoids to target the earliest oligomeric aggregates.
3.3.3 Phenylethanoid-modified Aβ1-42 Oligomers Fail to Exhibit Reduced Toxicity
To assess the ability of phenylethanoid-induced changes in Ab1-42 oligomer size
distribution to attenuate oligomer toxicity, caspase activity was evaluated following
treatment of SH-SY5Y human neuroblastoma cells with Aβ1-42 oligomers. Alone, 10 nM
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Aβ1-42 oligomers upregulate caspase activity by 40% (Figure C.1). Oligomers formed in
the presence of a 10-fold excess of either OLE, TOH, or TYR exhibit some reduction in
oligomer-induced

caspase

activity;

however,

this

difference

fails

to

reach

significance (Figure 3.4). An equivalent concentration of phenylethanoids is nontoxic (data
not shown). These results demonstrate that the observed phenylethanoid-induced changes
in Ab1-42 oligomer size distribution do not lead to a significant alteration in their ability to
induce toxicity.
3.3.4 Phenylethanoids Can Attenuate Ab1-42 Oligomer Toxicity Through Antioxidant
Mechanisms
Previous studies have demonstrated the ability of antioxidants to combat Aβinduced cell death [46]. When antioxidant capacity of phenylethanoids was assessed using
an ORAC assay, all three compounds were observed to be good antioxidants. Both OLE
and TOH exhibit antioxidant capacity somewhat higher than that of Trolox, a vitamin E
analog, while the antioxidant capacity of TYR is similar to Trolox (Figure 3.5A, open
bars). The effect of these antioxidants toward Ab oligomer-induced toxicity was evaluated
by assessing caspase activity within SH-SY5Y cells following simultaneous treatment with
10 nM oligomers formed in the absence of phenylethanoid and 10,000 nM phenylethanoid,
an antioxidant-capable concentration [82–84]. All three phenylethanoids demonstrate
some ability to reduce Aβ oligomer-induced caspase activation, with the most pronounced
effect observed for the strongest antioxidant, OLE (Figures 3.5A, hashed bars;
Figure 3.5B), but these changes do not reach significance. The impact of phenylethanoid
antioxidant action is illustrated, however, by the correlation between caspase activation
and phenylethanoid antioxidant capacity (Figure 3.5C).
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3.3.5 Phenylethanoids Exhibit a Multi-target Capability Toward Combating Aβ
Oligomer-induced Toxicity
Because oligomer-modification and antioxidant capabilities affect two distinct
therapeutic targets, phenylethanoids have the potential to act in a multi-target capacity to
mitigate the deleterious effects of Aβ. To assess this potential multi-target capacity, caspase
activity within SH-SY5Y cells was evaluated following simultaneous treatment with 10
nM Aβ1-42 oligomers formed in the presence of phenylethanoid and an antioxidant
dose (10,000 nM) of phenylethanoid.
As shown in Figure 3.6, all three phenylethanoids reduce oligomer-induced caspase
activity by more than 75% when acting simultaneously through oligomer-modification and
antioxidant capabilities. For OLE, this reduction is similar in magnitude to the effect
observed through antioxidant capacity alone. For TOH and TYR, this reduction is more
pronounced than that observed with either oligomer-modification or antioxidant
mechanisms alone. These results demonstrate the advantage of multi-target capabilities
exhibited by phenylethanoids.
3.4 Discussion
Epidemiological studies demonstrate a correlation between adherence to the MeDi
and incidence of AD [61–64]. Previous research has revealed that phenylethanoids
oleuropein aglycone and oleocanthal, compounds found in MeDi staple olive oil, have the
ability to target Aβ aggregates toward attenuating toxicity [48,75,76]. However, previous
studies examining olive oil have ignored its diverse chemical makeup and biological
capabilities, confining research to single compounds and mechanisms. The current study
investigated the therapeutic potential of three major phenolic components of olive oil [85].
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Phenylethanoid oleuropein (OLE) and metabolites released during olive oil production
hydroxytyrosol (TOH) and tyrosol (TYR) (Figure 3.1) were examined for their ability to
modulate Aβ aggregation and oligomerization as well as to act as antioxidants to attenuate
Aβ-induced cellular toxicity. Results indicate that while all compounds modulate
oligomerization, only OLE exhibits a holistic effect on the aggregation process, yet this
modulation does not translate to a reduction in oligomer-induced toxicity. OLE, TOH, and
TYR are also good antioxidants, which possess antioxidant capacities that correlate with
each compound’s mitigation of toxicity induced by pre-formed Ab oligomers. Ultimately,
the strength of these phenylethanoids lies in their ability to act dually through both
mechanisms to attenuate the physiological effect of Aβ oligomers.
The reported association between Aβ oligomers and cellular toxicity [10,77]
prompted investigation of the effect of phenylethanoids on oligomerization. Analysis of
early oligomeric aggregate species reveals that all three phenylethanoids reduce the
quantity of trimer and tetramer species (Figure 3.3D). However, a corresponding reduction
in monomer is also observed (Figure 3.3E), indicating that this effect does not stem from
inhibition. The inability of these compounds to inhibit the overall aggregation
pathway (Figure 3.2A; Table 3.1) further supports the propensity of phenylethanoids to
modulate oligomerization by shifting the equilibrium towards larger aggregates. In
contrast, phenylethanoids do not alter aggregate morphology (Figure 3.2B). In agreement
with these results, a previous study examining the structurally similar phenylethanoid
oleocanthal reported its capability to enhance the production of high order oligomeric
species, shifting the equilibrium state towards larger aggregate species [76]. A reduction
in aggregate formation, however, is not required to attenuate cellular toxicity [86].
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Numerous compounds, including phenylethanoid oleocanthal [76], peptide mimics [87],
polyphenols [88], and other small molecule modulators [58] have the ability to enhance
fibrillogenesis while also reducing neurotoxicity. In our study, however, the observed
phenylethanoid-induced changes in size distribution of oligomeric species result in only a
modest decrease in Ab-induced cellular toxicity (Figure 3.4).
While phenylethanoid-modified oligomers do not exhibit reduced toxicity, these
compounds are good antioxidants that, when acting through their antioxidant capacity
alone, exhibit a correlation between compound ORAC value and reduction in Aβ oligomerinduced toxicity (Figure 3.5). Powerful antioxidants can combat harmful ROS via
induction of numerous cellular pathways [52]. Earlier studies with phenylethanoids have
reported their ability to scavenge reactive nitrogen species as well as upregulate
intracellular mechanisms to combat these species [89]. Additionally, our lab has
demonstrated that antioxidant capability is a viable mechanism to attenuate Aβ-induced
toxicity [46]. Indeed, previous studies have reported the benefits of antioxidant rich diets
in countering AD pathophysiology [51,90].
While single-target therapeutics are valuable in mediating the pathophysiology of
AD, recent studies have illustrated the superior benefits of multi-target therapeutics [91–
93]. When acting dually through both antioxidant capabilities and modification of
oligomerization, all three phenylethanoids, OLE, TOH, and TYR, significantly reduce Ab
oligomer toxicity (Figure 3.6). In particular, for TOH and TYR the combination of effects
is greater than that exhibited by either mechanism alone. Together, our results demonstrate
that the ultimate strength of phenylethanoids lies not in an individual mechanism, but in
their multi-target capabilities.
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hydroxytyrosol (TOH)

oleuropein (OLE)

tyrosol (TYR)

Figure 3.1. Phenylethanoid structures. Structures of the olive oil derived
phenylethanoids, oleuropein (OLE), hydroxytyrosol (TOH), and tyrosol (TYR), studied for
their effect on Aβ aggregation and Aβ-induced toxicity.
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Figure 3.2. Phenylethanoid OLE modulates Aβ aggregation. SEC-purified Aβ1-40
monomer (20 µM) was incubated in 40 mM Tris-HCl (pH 8.0) in the absence (control,
CONT, ) or presence of a 10-fold molar excess of oleuropein (OLE, ), hydroxytyrosol
(TOH, £), or tyrosol (TYR, r). Samples were then diluted to a final Aβ concentration of
5 µM with 10 µM thioflavin T and 18.75 µM NaCl and subjected to continuous agitation.
A) Samples were monitored for thioflavin T fluorescence every 15 min until equilibrium
was achieved. Data are normalized to the lag time and equilibrium extent of aggregation
observed for the control, to yield relative time and relative fluorescence, and fit to a threestage kinetic model (Eqs. 1 and 2, solid lines). Results are representative of 4 independent
experiments. B) At terminal time points, aggregates were gridded and imaged by
transmission electron microscopy. Images are shown relative to a scale bar of 200 nm and
are representative of 4-5 independent experiments.
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Figure 3.3. Phenylethanoids modulate Aβ oligomerization. Aβ1-42 was solubilized
(150 µM) in DMSO in the absence (CONT) or presence of a 10-fold molar excess of
phenylethanoid. Oligomerization was initiated via subsequent dilution into 12 mM
phosphate (pH 7.4) containing 1 µM NaCl for a final concentration of 15 µM Aβ. After 30
min, oligomers were stabilized via the addition of Tween-20 (0.1%), resolved by SDSPAGE on either a 4-20% Mini-PROTEAN® TGX™ precast gel (panel A) or a 16.5%
Mini-PROTEAN® Tris-Tricine Gel (panel B), and detected following Western blot using
antibody 6E10. Images are representative of 4 independent experiments. Aggregate species
were quantified for pixel volume intensity within size ranges of 25-100 kDa (panel C, solid
bars) and 100-250 kDa (panel C, open bars) or within bands corresponding to trimeric
species (panel D, solid bars), tetrameric species (panel D, open bars), or monomeric species
(panel E). Results are normalized to the control, represented by a dashed line at 1. Error
bars indicate SEM, n=4. *p<0.05, **p<0.01, ***p<0.001 versus control.
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Figure 3.4. Phenylethanoid-modified oligomers fail to significantly reduce Aβ
oligomer-induced caspase activity. Ab1-42 oligomers formed in the absence (control) or
presence of a 10-fold molar excess of phenylethanoid were diluted in media for a final
concentration of 10 nM Aβ and used to treat SH-SY5Y human neuroblastoma cells.
Following 24-h incubation, cells were assessed for caspase activity via
immunocytochemistry and quantitative image analysis. A) Custom MATLAB functions
were used to calculate the percentage of caspase active cells. Results are reported relative
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to the control, represented by a dashed line at 1. Error bars indicate SEM, n=4. *p<0.05,
**p<0.01 versus control. B) Images for input into MATLAB were acquired following
staining of SH-SY5Y cells using Hoechst 33342 (blue) for nuclear detection, to enable
quantification of the total number of cells, and FLICA™ (green) for detection of activated
forms of caspase-1, -3, -4, -5, -6, -7, -8, and -9, to enable quantification of the number of
caspase activated cells. Individual and merged images are shown relative to a scale bar of
10 µm and are representative of 3 independent experiments.
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Figure 3.5. Antioxidant capable phenylethanoids can reduce Aβ oligomer-induced
caspase activity. An ORAC assay and Trolox standard were used to evaluate the
antioxidant capacity of phenylethanoids diluted in 75 mM potassium phosphate (pH 7.0)
(panel A, open bars). Results are reported as Trolox equivalent per molar concentration of
phenylethanoid, and the Trolox standard is represented by a dashed line at 1. Error bars
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indicate SEM, n=3. SH SY5Y human neuroblastoma cells were treated simultaneously
with 10 nM Aβ1-42 oligomers formed in the absence of phenylethanoid and 10,000 nM
phenylethanoid. Following 24-h incubation, cells were stained, imaged, and quantified as
described in Figure 3.4. The percentage of caspase active cells (panel A, hashed bars) is
reported relative to the control, represented by a dashed line at 1. Error bars indicate SEM,
n=3. Visualization of nuclear material (Hoescht 33342, blue) and activated caspases
(FLICA™, green) are shown alongside merged images (panel B). Images are shown
relative to a scale bar of 10 µm and are representative of 3 independent experiments. The
relationship between phenylethanoid antioxidant capacity and induced change in caspase
activation is evaluated via linear regression (r2 = 0.9323) (panel C).
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Figure 3.6. Phenylethanoids exhibit a multi-target capacity to reduce Aβ oligomerinduced caspase activity. SH-SY5Y human neuroblastoma cells were treated
simultaneously with 10,000 nM phenylethanoid and 10 nM Ab1-42 oligomers formed in the
presence of a 10-fold molar excess of phenylethanoid. Following 24-h incubation, cells
were stained, imaged, and quantified as described in Figure 3.4. The percentage of caspase
41

active cells (panel A) is reported relative to the control, represented by a dashed line at 1.
Error bars indicate SEM, n=3-4. *p<0.05, **p<0.01, ***p<0.001 versus control.
Visualization of nuclear material (Hoescht 33342, blue) and activated caspases (FLICA™,
green) are shown alongside merged images (panel B). Images are shown relative to a scale
bar of 10 µm and are representative of 3 independent experiments.
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CHAPTER 4
SOY ISOFLAVONES ACT VIA MULTIPLE DISTINCT PATHWAYS TO
ATTENUATE AMYLOID-Β OLIGOMER INDUCED TOXICITY IN
SH-SY5Y CELLS
4.1 Introduction
Soy, an edible bean native to Asia, is a vegetable processed into tofu, soy milk, or
other food additives [94]. While the exact benefit of soy have long been shrouded in
controversy [95–98], studies have shown soy isoflavones (SIFs), a group of polyphenols
found in abundance in soy, are promising nutraceuticals[99,100].
In diseases such as cardiovascular disease, prostate cancer, menopause, and breast
cancer, SIF effectiveness has been attributable to their potent antioxidant capacity [101–
104]. And recent studies have demonstrated the ability of SIFs and polyphenols in general
to ameliorate both the etiology and symptoms of neurodegenerative diseases [105–109].
Of particular interest in this work, SIFs have shown promise in combating the harmful side
effects of amyloid-β, the protein associated with Alzheimer’s disease [110–113].
Alzheimer’s disease is the most common neurodegenerative disease and is
characterized by the deposition of insoluble plaques of aggregated Aβ [114]. While plaques
are often observed post-mortem, studies have shown that oligomers, a group of transient
intermediates formed during aggregation, are acutely neurotoxic species [10,23,77,115]. In
fact, oligomers have been shown to produce potent oxidizing species which are theorized
to contribute significantly to the disease state. Recent studies have expounded on the
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benefits on polyphenols for their anti-aggregation potential as well as their ability to
directly counteract toxic ROS via their antioxidant capacities [50,54,80]. While SIFs have
been investigated as it relates to AD, mechanistic insight has been poorly studied.
The present study looks at two major SIF constituents, genistin (OGEN) and
daidzin (ODEN), as well as their primary metabolites genistein (GEN) and daidzein
(DEN), to determine their holistic effects on Aβ1-42 oligomers (Figure 4.1A). Results
demonstrate that each SIFs exhibits protective effects when both present during Aβ1-42
oligomerization and allowed to activate cellular responses. OGEN and GEN, SIFs
possessing enhanced hydroxylation, were more effective than ODEN and DEN. Although
aggregate morphology was largely unchanged, all four SIFs reduced lag time to aggregate
formation, three SIFs (OGEN, ODEN, and DEN) increased aggregation rate, and the two
glycosylated SIFs (OGEN and ODEN) significantly enhanced the extent of aggregation.
Contrastingly, there was no holistic effect on oligomeric size, distribution, or conformation.
Ultimately, the resulting oligomer associated caspase activation was unaffected. In our
study, we found SIFs are good antioxidants, and several SIFs (GEN, ODEN, and DEN)
can increase the relative activity of catalase, a hydrogen peroxide reducing enzyme. Only
DEN-induced antioxidant responses had an effect on oligomer associated caspase
activation. This study ultimately revealed that SIF-associated caspase activation observed
initially can be attributed to a unique mechanism. ODEN acts equally well through either
its anti-aggregation effects or as an antioxidant, while OGEN has a clear additive effect.
DEN is dominated by one mechanism: it modulates toxicity similar to its antioxidant
capacity. The most interesting SIF, however, is GEN which exhibits a synergistic response
between mechanisms.
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4.2 Materials and Methods
4.2.01 Materials
Soy isoflavones genistin (OGEN), genistein (GEN), daidzin (ODEN), and daidzein
(DEN) were purchased from Indofine Chemical Company (Hillsborough, NJ). All SIFs
were freshly dissolved in DMSO immediately prior to use.
4.2.02 Aβ1-42 Oligomerization
Aβ1-42 oligomers were first prepared as described in Section 2.06. DMSOsolubilized SIFs were added to Aβ to obtain a 10:1 ratio of SIF:Aβ. An equivalent volume
of DMSO alone served as the control. Resultant oligomers were then diluted in cell culture
media, diluted with 0.1% Tween-80, or otherwise used immediately.
4.2.03 Cell Treatment
Cell were maintained and seeded as described in Section 2.09. Cell treatments, as
described in Section 2.10, were either with 1) 10,000 nM SIF and 10 nM oligomers formed
in the presence of 100 nM SIF, 2) 10 nM oligomers formed in the presence of 100 nM SIF,
or 3) 10,000 nM SIF and 10 nM oligomers formed in the absence of SIF. Alternatively,
cells were treated with 1.5 U TNF-a to serve as the positive control
4.2.04 Assessment of Cellular Apoptosis
After a 24 h treatment (Section 4.2.03), cells were stained and imaged as described
in Section 2.11 using the Image-iT® LIVE Green Poly Caspases Detection Kit (Life
Technologies). Cells were imaged within 24 hours using a using a Nikon Eclipse Ti-E
fluorescent microscope (Melville, NY) and Nikon NIS-Elements 3.0. Images were
acquired in the two channels: Hoechst (blue) and FLICA™ (green). Results were
quantified using a custom MATLAB code (Appendix B and C) and results were reported
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as percentage of caspase active cells. The relative percentage for each image was averaged
across slides and normalized to the control (Aβ alone). A value of 1 represents no change
in caspase activity as compared to Aβ alone while a value of 0 represents the complete
reduction of activity.
4.2.05 Aβ1-40 Monomer Aggregation
Monomer was aggregated as described in Section 2.03. Using SEC-purified
monomer (Section 2.02), Aβ1-40 was aggregated in the presence of a 10-fold excess of SIF.
Final reaction samples contained 5 µM Aβ1-40 monomer, 50 µM phenylethanoid, 18.75 mM
NaCl, and 10 µM ThT, a dye that excites in the presence of β-structure. Samples were
loaded in triplicate onto a 96-well plate, sealed to prevent evaporation, and continuously
agitated. Fluorescence was monitored until a plateau was reached for all samples.
4.2.06 Transmission Electron Microscopy Imaging
At terminal time points, aggregate morphology was examined using TEM as
described in Section 2.05. Aggregates (Section 4.2.05) were loaded on to a copper grid and
negatively stained with uranyl acetate. Images were acquired using a JEOL 1400 Plus
Transmission Electron Microscope accelerated at 120kV.
4.2.08 Kinetic Modeling
The effect of SIFs on Aβ aggregation kinetics was assessed as described in Section
2.04. The fluorescence data for the control (Section 4.2.05) were fit to Equations 1 and 2.
Using the obtained values for the amplitude (A) and lag time to aggregate formation (tlag),
data for SIFs were normalized to the relative plateau and relative time. A value less than 1
represents a decrease compared to the control where as a value greater than 1 represents an
increase.
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4.2.09 Assessment of Oligomer Size and Distribution
To characterize the effects of SIFs on Aβ1-42 oligomer size and distribution,
oligomers (Section 2.06) were resolved using SDS-PAGE with Western blot as described
in Section 2.07. Densiometric analysis was conducted over monomer, trimer, and tetramer
bands for each as well as oligomer presenting regions from 250–100 kDa and 100–25 kDa.
Results are expressed as the intensity fraction compared to the control. A value of 1
represents no change from the control and a value less than 1 represents a reduction in the
quantity of oligomers.
4.2.10 Assessment of Aβ1-42 Oligomer Conformational Changes Using ANS
Spectroscopy
The effect of SIFs on Aβ oligomer conformation was assessed using 8-Anilino-1naphthalenesulfonic acid (ANS) as described in Section 2.08. Oligomers formed in the
presence of SIFs were diluted in ANS to a final concentration of 1 µM oligomer, 10 µM
SIF (or DMSO for the control), and 50 µM ANS. Sample fluorescence was measured from
400-600 nm. Integrated area under the curve was calculated from 450-550 nm. Blanks,
samples containing only SIF (or DMSO) and ANS, were also obtained for each sample.
Results were then blank subtracted and normalized to the control (oligomers alone).
4.2.11 Total Antioxidant Capacity
As described in Section 2.13, antioxidant capabilities were assessed using the
QuantiChrom™ Antioxidant Assay Kit. Briefly, Trolox standards were prepared from
1000 µM to 0 µM and loaded onto a clear bottom 96-well plate. SIF samples were diluted
to 1.33 µM using Working Reagent and incubated at room temperature for 10 mins.
Absorbance was then measured at 570 nm on a Spectramax 190 Microplate Reader
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(Molecular Devices, Sunnyvale, CA). A Trolox standard curve was then constructed by
plotting absorbance against concentration and TAC values (µM Trolox equivalencies) were
calculated by normalizing SIF samples to an equivalent of Trolox alone (TAC = 1).
4.2.12 Catalase Activity Assay
The effect of SIFs on catalase was assessed using the Amplex™ Red Catalase Kit
as described in Section 2.14. 800 µM SIF was incubated with 125 mU/mL catalase before
dilution with 40 µM H2O2 in 96-well plate. Following a 30 min incubation at room
temperature, samples were further diluted to 100 µM SIF and 31.25 mU/mL catalase using
100 µM Amplex™ Red and 1U HRP and incubated for 30 mins at 37°C. Absorbance was
measured the net absorbance was reported by subtracting the sample or standard from the
blank (0 mU/mL). Using the catalase standard curve, SIF values were then converted into
an equivalent catalase concentration and normalized to catalase alone. Results are reported
as a fraction of control. A value of 1 represents no increase in activity from the control
while a value greater than 1 represents an increase in catalase activity.
4.3 Results
4.3.1 SIFs attenuate Aβ1-42 oligomer-induced toxicity
SH-SY5Y human neuroblastoma cells were treated concurrently with 10,000 nM
SIF and 10 nM Aβ1-42 oligomers formed in the presence of a 10-fold molar excess of SIF.
Following

24-h

incubation,

cells

were

evaluated

for

caspase

activity

via

immunocytochemistry with quantitative image analysis. As shown in Figure 4.1B-C, the
upregulation of caspase activity induced by Aβ1-42 oligomers (Appendix D, Figure D.5)
was significantly attenuated by all four SIFs (OGEN, GEN, ODEN, and DEN). SIF
effectiveness ranges from a 60% reduction in caspase activity (DEN) to a 90% reduction
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(OGEN). While glycosylated compounds (OGEN and ODEN) exhibit a slightly greater
ability to decrease oligomer-induced caspase activation than the non-glycosylated
compounds (GEN and DEN), this difference did not reach significance. However, a
significant difference in reduction of oligomer-induced caspase activation is observed
between hydroxylation states, indicating that the presence of a hydroxyl on the 5 position
increases effectiveness.
4.3.2 SIFs alter Ab1-40 aggregation kinetics
To explore inhibition of aggregation as a mechanism of SIF protection from Ab
oligomer induced toxicity, SEC purified Aβ1-40 monomer was agitated in the presence of a
10-fold excess of SIF (Figure 4.2A), a 2-fold excess of thioflavin T to facilitate detection
of aggregates, and 18.75 µM NaCl to promote aggregation. All kinetic curves exhibited a
characteristic lag period, subsequent exponential growth, and a plateau in thioflavin T
fluorescence as equilibrium is reached (Figure 4.2A). Accordingly, data were fit to a
sigmoidal growth curve (Eqs. 1 and 2, Figure 2A solid lines) to determine the lag time to
aggregate formation (tlag), the rate of aggregate formation during the growth phase (k), and
the extent of aggregation at equilibrium (A) (Figure 4.2B). All SIFs significantly reduced
tlag, and three SIFs (OGEN, GEN, and DEN) increased k. However, only glycosylated SIFs
(OGEN, ODEN) had a significant effect on A, increasing the extent of aggregation by
greater than 2-fold.
At terminal time points, aggregates were gridded and imaged via TEM to assess
morphological changes (Figure 4.2C). Images of control aggregates, formed in the absence
of SIFs, reveal a typical Aβ1-40 fibril morphology: fibers of varying lengths and sizes that
exhibit both lateral and longitudinal growth. Aggregates formed in the presence of ODEN,
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OGEN, and GEN exhibit a similar morphology. In contrast, DEN-modified aggregates are
more densely packed than control fibrils.
4.3.3 GEN and ODEN impact size distribution of Aβ1-42 oligomers
The effect of SIFs on formation of early aggregate species was studied using Aβ1-42
oligomers formed in the absence (control) or presence of a 10-fold molar excess of each
SIF via dilution from DMSO into aqueous buffer. Resulting oligomers were resolved using
SDS-PAGE and Western blot, with resolution of 25-250 kDa oligomers on a 4-20% Trisglycine gel (Figure 4.3A) and resolution of monomeric, trimeric, and tetramer species on
a 16.5% Tris-tricine gel (Figure 4.3B). Densiometric analysis of Western blots reveals a
significant effect on the formation of 100-150 kDa oligomers only by GEN and on 25-100
kDa oligomers only by ODEN (Figure 4.3C). In contrast, none of the SIFs tested alter the
formation of tetrameric or trimeric oliogmers (Figure 4.3D) or the quantity of residual
monomer (Figure 4.3E).
4.3.4 SIFs have negligible effect on Aβ1-42 oligomer conformation
To investigate the effect of SIFs on the conformation of early Ab aggregates, Ab1-42
oligomers formed in the absence (control) or presence of a 10-fold molar excess of SIF
were examined for their abiilty to bind ANS, a fluorescent molecular dye that excites when
bound in proximity to hydrophobic surfaces. Ab1-42 oligomers formed in the presence of
ODEN (Figure 4.4) exhibit some increase in ANS fluorescence, indicative of an
enhancement of surface hydrophobicity; however, this change fails to reach significance.
Oligomers formed in the presence of OGEN and DEN exhibit a slight, but insignificant,
reduction in ANS fluorescence, while oligomers formed in the presence of GEN exhibit an
ANS fluoescence identical to that of control oligomers.
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4.3.5 Aβ1-42 oligomers formed in the presence of SIFs are unaltered in toxicity
To explore the effect that SIF-induced modifications of oligomer size and
morphology may have upon toxicity, SH-SY5Y human neuroblastoma cells were treated
with 10 nM Aβ1-42 oligomers formed in the absence (control) or presence of a 10-fold molar
excess of SIF. After 24 h, caspase activity was evaluated via immunocytochemistry with
quantitative image analysis (Figure 4.4, solid bars). Oligomers formed in the presence of
each SIF exhibit a slight reduction in toxicity, with the most pronounced change observed
for ODEN. However, these differences do not reach significance.
4.3.6 SIFs are potent antioxidants
To assess the intrinsic antioxidant capabilities of SIFs, their TAC was measured,
Results, shown in Figure 4.5A (white diamonds), indicate that SIFs are equivalent or better
antioxidants compared to vitamin E analog Trolox (dashed line at 1). While ODEN and
DEN are good antioxidants with a TAC similar to Trolox, OGEN and GEN were
significantly stronger antioxidants. Additionally, OGEN and GEN were significantly better
antioxidants than ODEN and DEN, respectively.
As an alternative to intrinsic antioxidant capabilities, compounds can also exert an
antioxidant effect by activating intracellular antioxidant processes. To examine this
possibility, the ability of SIFs to activate catalase, a hydrogen peroxide catalyzing enzyme,
was evaluated using the Amplex™ Red Catalase Kit. GEN, ODEN, and DEN all
significantly increase catalase activity, with the most pronounced difference observed for
GEN and DEN (Figure 4.5A, black diamonds). In contrast, catalase activity is unchanged
by the presence of OGEN.
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4.3.7 Antioxidant DEN reduces Aβ1-42 oligomer-induced toxicity
To explore the effect that SIF antioxidant actions have upon Aβ1-42 oligomerinduced caspase activation, SH-SY5Y human neuroblastoma cells were cultured in the
presence of 10,000 nM SIF and 10 nM Aβ1-42 formed in the absence of SIF. Following 24h treatment, cells were evaluated for caspase activity via immunocytochemistry and
quantitative image analysis (Figure 4.5B). OGEN (p = 0.0518) and ODEN (p = 0.0513)
exert a slight but insignificant effect on Ab oligomer-induced caspase activation. The
presence of DEN, however, significantly attenuated oligomer-induced caspase activation
by greater than 60%.
4 Discussion
For decades, soy isoflavones (SIFs) have been mistakenly labeled as dangerous
[116,117]. Initially investigated as hormone replacements [116,118], SIFs have taken on a
second life as therapeutics for a variety of neurological conditions [102,104,119,120] and
studies show a strong neuroprotective effect [113,121–123] . This study assessed the effect
of the four most abundant SIFs, genistin (OGEN), genistein (GEN), daidzin (ODEN), and
daidzein (DEN), on their ability to attenuate Aβ1-42 oligomer-induced toxicity.
Additionally, it attempted to determine whether each SIF acted through anti-aggregation
effects, cellular processes, or some combination of both. Our results showed that all four
SIFs reduce toxicity in our model when both mechanisms are allowed to act in concert.
While all four SIFs impacted some combination of aggregation lag time and rate, only
glucosides OGEN and ODEN impacted the extent of aggregation. And, while some SIFs
had modest effects on oligomer size and distribution, these anti-aggregation effects had no
impact on aggregate toxicity. More importantly, and in agreement with published
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works [102,104,121], their antioxidant potential was strong with two SIFs (OGEN and
GEN) significantly increasing antioxidant capabilities. Additionally, results indicate
several SIFs (GEN, ODEN, and DEN) increase catalase activity, an enzyme responsible
for hydrogen peroxide metabolism. DEN, the SIF with the greatest increase in catalase
activity, effectively modulated caspase activation similarly to our initial findings .
Ultimately, we determined that each SIF acts in a different manner (Figure 4.6). While
DEN acts through its antioxidant effects, OGEN (additive) and ODEN (neither dominates)
act through a singular mechanism. GEN, uniquely, exhibits synergistic potential.
In line with previous in vitro studies [108,124,125], SIFs (Figure 4.1A) exhibited a
50-80% reduction in toxicity (Figure 4.1B - C). However, it unclear if this was due to their
anti-aggregation or widely cited antioxidant effects. Our initial goal, therefore, was to
identify the mechanism for each SIF: either anti-aggregation effects or interaction with
intracellular processes. With little exception, previous aggregation studies have looked at
the effect of one of more SIFs in the presence of cells [111,122,125,126]. Therefore we
focused directly on protein-SIF interaction and show the four SIFs significantly reduce the
lag time and three of the four (OGEN, GEN, and DEN) have an effect on the rate. Only
glycosides ODEN and OGEN have an effect on the extent of aggregation (Figure 4.2A-B)
and SIFs have minimal effect on morphology (Figure 4.2C). This result is not without
precedence. Studies have suggested that Aβ is able to intercalate glucose into its structure,
enhancing aggregation [127]. This phenomena has been further confirmed in studies of
type 2 diabetes where patients have an enhancement of the extent of aggregation [128,129].
However, our observed aggregation enhancement did extend to oligomers. In fact,
only a slight effect was observed in either oligomer quantity (Figure 3C) or conformation
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(Figure 4.4A, checkered bars) with the largest oligomeric response a conformational shift
with ODEN. While polyphenols are typically associated with neuroprotective benefits, this
is not necessarily the case for all polyphenols [46,47]. Unsurprisingly, the anti-aggregation
effects of SIFs had no effect on toxicity (Figure 4.4A, solid bars) Taken together, these
results are indicative of a lack of significant SIF-Aβ interaction.
Previous studies have correlated SIFs antioxidant capacities with their ability to
attenuate oxidative stress and mitochondrial dysfunction induced via Aβ1-42 aggregates
[111,121,125]. Similarly, our study showed that SIFs were good antioxidants (Figure 5A,
white diamonds). While only OGEN and GEN were significantly better antioxidants,
ODEN and DEN possess an antioxidant capacity as good a vitamin E analog Trolox.
Previous studies from Lee et. al [130] also showed indistinguishable antioxidant capacities
between aglycon SIFs and their corresponding glucosides. Some in vivo studies have also
shown an increase in catalase response when a SIF containing mixture is used. [131]
Additionally, Kampkötter et. al [132] presented a second potential antioxidant target: DEN
catalase, an enzyme responsible for the metabolism of hydrogen peroxide. Likewise, our
results indicate three SIFs, GEN, ODEN, and DEN, have the ability to increase catalase
activity (Figure 4.5B, black diamonds). DEN, additionally is both a very good antioxidant
and able to upregulate catalase activity.
Aside from DEN, our results have still not explain the sharp reduction in SIF
toxicity observed in Figure 4.1B-C: the motivation for the study. However, when the
toxicity studies are compared (Figure 6A), we see the true potential of each SIF. OGEN
has a clear additive effect: when SIFs are allowed to modulate both aggregation and
intracellular processes, the effect is roughly equal to the combination of the two. ODEN,
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however, has no preference for either mechanism. DEN, likely thanks to its antioxidant
capacity and interaction with catalase, acts through antioxidant effects alone.
GEN, interestingly, has a synergistic response to Aβ1-42 oligomer-induced toxicity.
While these our study looked at two antioxidant processes options, there are many
molecular targets for SIFs to act upon in vivo. GEN, for instance, has the ability to act
through NrF-2 [125]. Additionally, studies have shown GEN can modulate downstream
molecular targets such as the AD-associated tau protein [122].
Kampferol (KAE), a flavone structurally similar to GEN (Figure 6B), has shown
comparable response to Aβ1-42 oligomer-induced caspase activation. While studies have
shown KAE’s propensity to enhance fibril formation [133], a recent study from our group
has shown that, just like GEN, KAE possesses a unique synergistic effect between antiaggregation effects and antioxidant effects to reduce toxicity [46]. This is an effect not
observed in either structural analog DEN or OGEN.
Ultimately, our results continue to show SIFs exhibit potential for the treatment of
AD. However, it isn’t entirely attributable to their widely publicized antioxidant power.
Instead our results found that SIFs have many effect on the Aβ1-40 aggregation process but
no effect on Aβ1-42 oligomers. Instead, SIFs modulate toxicity through a variety of
mechanisms: while DEN uses antioxidant means to ameliorate toxicity ODEN acts equally
as well through anti-aggregation and antioxidant means. ODEN acts through the
combination of anti-aggregation plus antioxidant effects. Finally, GEN creates a
synergistic effect on Aβ toxicity with a reduction greater than either of the individual
components. Ultimately, this study shows that SIFs are promising multi-target therapeutic
targets to ameliorate Aβ induced cell response.
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Figure 4.1. SIFs reduce Ab toxicity. A) Four SIFs were studied for their mechanistic
effects on Aβ toxicity, including genistin (OGEN) and daidzin (ODEN) as well as their
aglycon metabolites genistein (GEN) and daidzein (DEN). B) SH-SY5Y human
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neuroblastoma cells were treated simultaneously with 10,000 nM SIF plus 10 nM Ab1-42
oligomers formed in the presence of 100 nM SIF. After 24 h, cells were stained and imaged
using FLICATM to detect active caspases and Hoechst 33342 to detect nuclei. Images were
quantified using a custom MATLAB script to determine the fraction of caspase active cells
(gray bars) relative to treatment with 10 nM Aβ1-42 oligomers alone (control, dashed line
at 1). Error bars indicate SEM, n=4. *p<0.05, **p<0.01, ***p<0.001 versus control.
†p<0.05 between isoflavones. C) Images of FLICATM fluorescence, representative of 4
independent experiments, are shown relative to a scale bar of 10 µM. Coinciding Hoescht
33342 images can be found in Appendix D, Figure D.2.
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Figure 4.2. SIFs modulate Aβ aggregation. SEC-purified Aβ1-40 (20 µM) was incubated
in 40 mM Tris-HCl (pH 8.0) in the absence (CONT, control, ✷) or presence of a 10-fold
excess of genistin (OGEN, n), genistein (GEN, £), daidzin (ODEN, ), or daidzein
(DEN, ). Samples were then diluted to a final concentration of 5 µM Aβ, 10 µM
thioflavin T, and 18.75 µM NaCl. A) Samples were subjected to constant agitation and
fluorescence was measured every 15 min until equilibrium was achieved. Aggregation
curves shown are representative data from 4-5 independent experiments. Data were
normalized to the CONT fit on a typical sigmoidal curve (Eq. 1, solid line). B) SIF samples
were then normalized to the lag (Eq. 2) and plateau equilibrium and data for each sample
was fit to the three-phase growth curve. C) At terminal time points, aggregates were
gridded and imaged at 20,000 X (top, scale bar = 200 nm) or 30,000 X (bottom, scale
bar = 100 nm). Error bars indicate SEM, n=4-5. *p<0.05, **p<0.01 versus control.
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Figure 4.3: Effect of SIFs on Aβ oligomerization. Aβ1-42 was solubilized in DMSO alone
(CONT) or in the presence of a 10-fold molar excess of SIF and diluted to 15 µM using
12 mM phosphate buffer (pH 7.4) containing 1 µM NaCl. Following 30-min incubation,
oligomers were stabilized via Tween-20 (v/v 0.1%) and resolved using SDS-PAGE on
either a 4-20% Tris-glycine gel (panel A) or a 16.5% Tris-Tricene gel (panel B). Aggregate
species were detected following Western blot using 6E10 antibody and densiometrically
quantified within the size ranges of 100-250 kDa (panel C, horizontal hashed bar) and 25100 kDa (panel C, vertical hashed bar) or within bands corresponding to trimeric (panel D,
horizontal hashed bar), tetrameric (panel D, vertical hashed bar), and monomeric species
(panel E, horizontal hashed bar). Results are normalized to the control, represented by a
dashed line at 1. Error bars indicate SEM, n=3. *p<0.05 versus control.
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Figure 4.4: Effect of SIFs on Ab oligomer conformation and the impact of SIF antiaggregation capabilities upon Ab oligomer toxicity. Aβ1-42 oligomers were formed as
described in Figure 3 in the absence (CONT) or presence of 10-fold excess SIF. Oligomers
were diluted to 1 µM Aβ and 10 µM SIF in the presence of 50 µM ANS. ANS fluorescence
was integrated from 450-550 nm and blank (50 µM ANS, 10 µM SIF) subtracted
(checkered bars). Results are normalized to the control, indicated by a dashed line at 1.
ANS emission scans are presented in Appendix D, Figure D.1. Oligomers were also diluted
to 10 nM in cell culture media and used to treat SH-SY5Y human neuroblastoma cells.
After 24-h, cells were stained, imaged, and quantified to determine the percentage of
caspase active cells (solid bars), as described in Figure 4.1. Results are normalized to the
control, indicated by a dashed line at 1. Error bars indicate SEM, n=3-4. FLICATM and
Hoescht images are presented in Appendix D, Figure D.3.

60

A

B

Figure 4.5: SIF antioxidant capabilities and the associated impact upon Ab oligomer
toxicity. A) To assess intrinsic antioxidant capabilities, the TAC for each SIF was
measured using the QuantiChrom™ Antioxidant Assay Kit. Results are reported as an
equivalent concentration of the Trolox standard (white diamond bars). The Trolox standard
is indicated by a dashed line at 1. Error bars indicate SEM, n=4. *p<0.05. Alternatively, to
assess the ability of SIFs to activate intracellular antioxidant processes, SIF-induced
changes in the activity of hydrogen peroxide metabolizing enzyme catalase were measured
using the AmplexTM Red Catalase Kit when 125 µM catalase was incubated in the presence
of 800 µM SIF and 40 mM H2O2. Results are reported as a fold-increase in catalase activity
(black diamond bars) relative to the activity of 125 µM catalase alone, indicated by a
dashed line at 1. Error bars indicate SEM, n=4. *p<0.05. B) Oligomers formed as described
in Figure 4.1 in the absence of SIFs were diluted to 10 nM in cell culture media
concurrently with addition of 10,000 nM SIF and used to treat SH-SY5Y human
neuroblastoma cells. After 24-h, cells were stained, imaged, and quantified to determine
the percentage of caspase active cells (solid bars), as described in Figure 4.1. Results are
normalized to caspase activity for cells treated with 10 nM Aβ1-42 oligomers alone (control,
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dashed line at 1). Error bars indicate SEM, n=3. *p<0.05. FLICATM and Hoescht images
are presented in Appendix D, Figure D.4.
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Figure 4.6: SIFs act through unique mechanisms. SIFs were tested for their ability to
act through anti-aggregation effects (solid bars), cellular processes (open bars) or the
combination of the two (grey bars). Results shown previously were converted to a percent
reduction where 0 is equivalent to no change from the control and 100% is a complete
elimination of caspase activity. While DEN acted primarily through antioxidant potential,
ODEN, GEN, and OGEN had unique mechanisms. B) A comparison between GEN and
KAE, two structurally similar compounds that both attenuate Aβ induced toxicity through
synergistic means. Error bars indicate SEM, n=4. *p<0.05, **p<0.01 versus control.
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CHAPTER 5
ASSESSMENT OF THE ROLE OF THE AMYLOID-β GLYCINE ZIPPER
IN AGGREGATION
5.1 Introduction
Amyloid proteins are known for their propensity to misfold. Additionally, they are
at the center of a variety of debilitating degenerative diseases such as Alzheimer’s disease
(AD) and the amyloid-β protein (Aβ). Aβ is formed in vivo from the amyloid precursor
protein (APP), a transmembrane protein that plays a role in cellular adhesion [134]. After
APP undergoes a series of cleavage events, Aβ is secreted as a monomeric peptide. While
the cause is unclear, monomer will begin to aggregate following a nucleation event and
form toxic aggregates [31]. As Aβ aggregates, it develops a characteristic β-sheet structure
and fibril morphology as the tertiary structure evolves [135]. Ultimately, these fibrils will
deposit in the brain as the insoluble plaques frequently associated with AD [136].
While work continues to enhance the understanding of higher order Aβ structure,
recent works have focused on a poorly understood region of the primary structure: a Cterminal glycine zipper motif (GxxxG). Glycine zippers are highly conserved in
transmembrane proteins (TMP) [137], such as the region in APP from which Aβ is derived.
Kim et. al explored the role of glycine zippers in vivo [138], finding zippers inside TMPs
associated with prion, influenza, and myelin. It has been theorized that glycine zippers
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The Aβ glycine zipper is of particular interest for its links to toxicity [139–141].
Several mutations to the zipper region have been identified, such as the Flemish mutation,
which replaces an alanine (A) with a glycine (A21G), and the Arctic mutation, which
replaces a glutamic acid (E) with a glycine (E22G). Both of these mutations extend the
zipper an extra unit and are associated with early onset AD and prominent vascular
hemorrhage associated with vascular Ab aggregate deposition [142]. Studies have shown
that mutations in the zipper region can promote oligomerization [140,143,144]. However,
some mutations to the zipper actually decrease toxicity in vivo [139]. Targeting either G29,
G33, or G37 can reduce Aβ toxicity relative to the wild type form of Aβ (WT). These
residues block both aggregation and cellular interaction, and as a result, zippers have been
used to reverse engineer a therapy that inhibits aggregation, reduces cellular interaction,
and ameliorates toxicity [56].
This study explores the role of the glycine zipper in Aβ aggregation through single
and double point mutations. Mutants, shown in Figure 5.1, were selected for their ability
to modify the zipper. To increase the motif, mutations were selected that expanded upon
two naturally occurring and extensively studied mutations, A21G and E22G. Our variants,
V18G E22G and L17G E22G, add an extra glycine zipper motif onto each familial mutant.
Additionally, V18G E22G is shifted one unit, whereas L17G A21G is a direct extension.
This study also explored the reduction of the glycine zipper by targeting G25 and replacing
it with either a similarly small alanine (A) or bulky isoleucine (I). Preliminary results
indicate that mutations with an extended zipper region rapidly aggregate, leading to the
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formation of small aggregates with a similar morphology to the WT. Additionally,
interference at G25 results in aggregates that are much more fibrillar but lack the typical
lateral stacking associated with WT Aβ. Additionally, results indicate that the relative
amount of soluble aggregates was increased when the zipper region was enhanced and
reduced when it was decreased. Overall, results indicate that the glycine zipper plays an
important role in Aβ aggregation and warrants further study.
5.2 Materials and Methods
5.2.01 Materials
Lyophilized Aβ WT and mutants, as described in Figure 5.1, were obtained from
Peptide 2.0 (Chantilly, VA).
5.2.02 Monomer Aggregation
WT Aβ1-40 and mutants were purified as described in Section 2.02. Aggregation, as
described in Section 2.03, was monitored within reactions containing 20 µM SEC-purified
monomer, 30 mM NaCl, and 40 µM thioflavin T. Reaction mixtures were loaded onto 30
wells of a 96-well plate and covered with sealing tape to prevent evaporation. Reactions
were agitated to promote aggregation and fluorescence measurements were acquired every
15 min until plateau fluorescence was observed for all samples.
5.2.03 Transmission Electron Microscopy
At terminal time points of aggregation (5.2.02), samples were prepared for TEM as
described in Section 2.05. Mutant samples were added to grids and negatively stained with
uranyl acetate. Images were acquired using a JEM 1400 Plus Transmission Electron
Microscope accelerated to 120kV.
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5.2.04 Modeling of Amyloid-β Aggregation
Aggregation data (5.2.02) were fitted using a the advanced model as described with
equations 3, 4, 5, and 6 in Section 2.04. Parameters were calculated representing the lag
time (tlag), the growth rate (k), and the equilibrium plateau (A) from the growth phase as
well as the final plateau (B), the decay phase rate constant (c), and the decay phase lag
period tend. Using a robust fit method and program identified initial values, the model was
iterated until convergence or 100,000 times, whichever occurred first.
5.2.06 Hydrodynamic Radii Assessment
Dynamic light scattering (DLS) was used to determine the aggregate hydrodynamic
radius, as described in Section 2.15. 10 µL of each aggregation end product (5.2.02) was
loaded into a quartz cuvette, and 50 acquisitions were averaged to obtain a hydrodynamic
radius (RH). Results for each sample are reported.
5.2.07 Assessment of Aggregate Conformation using ANS Spectroscopy
As described in Section 2.08, ANS spectroscopy was used to assess surface
hydrophobicity. ANS was diluted to 997.5 µM in Tris-HCl (pH 8.0) and was used to dilute
aggregation end products (5.2.02) to a final concentration of 1.33 µM protein and 66.5 µM
ANS, a 50-fold excess. Sample fluorescence was measured, and fluorescence area was
calculated, blank subtracted, and reported.
5.2.08 Quantification of Soluble Aggregate
Aggregation

end

products

(5.2.02)

were

subjected

to

size

exclusion

chromatography as described in Section 2.02. Samples were loaded onto a SEC column
pre-treated with 0.5 mg BSA and their absorbance was measured using UV absorbance
(280 nm).
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5.3 Results
5.3.1 Glycine zipper plays a role in aggregation kinetics
Aβ monomer was aggregated in the presence of a 2-fold excess of thioflavin T and
30 µM NaCl. Samples were subjected to continuous agitation and monitored for 48 h
(Figure 5.2A-D). Data were then fit using a novel method to accurately capture the post
plateau change occurring after lag. While the model accurately reflects features for three
samples, it does not capture the peak in either V18G E22G or G25A.
Preliminary fits, shown in Figure 5.2 indicate that, compared with the WT (Figure
5.2A), L17G A21G (Figure 5.2B) and V18G E22G (Figure 5.2C), mutations that extended
the glycine zipper, accelerate aggregation, with aggregates beginning to form within the
first hour. Meanwhile, G25A (Figure 5.2D), a mutation that reduces the glycine zipper,
result in aggregates with a lag time similar to the WT. G25I, because of its diminished
fluorescence, was unable to be fit to the model. Extent of aggregation is also impacted by
glycine zipper mutations. While V18G E22G, the off-sequence mutation, results in an
equilibrium roughly equivalent to the WT control, L17G A21G greatly enhances the extent
of aggregation. Similarly, G25A, which replaces a glycine with similarly sized alanine,
increases the extent of aggregation, while substitution with an isoleucine (G25I) inhibits
the formation of thioflavin T positive aggregates.
5.3.2 Glycine zipper mutations alter aggregate morphology
Following aggregation, samples were loaded on grids, negatively stained, and
imaged via TME for morphological changes (Figure 5.3). Compared to the WT which
possess fibrils of varying lengths and width that form an interwoven mesh network, image
obtained for glycine zipper mutations which increase the zipper length (L17G A21G and
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V18G E22G, Figures 5.3B and C) create much smaller aggregates compared to the WT
(Figure 5.3A). While L17G A21G has an amorphous structure, V18G E22G aggregates
have a more typical, albeit truncated, fibril morphology. Conversely, G25A and G25I
mutations (Figures 5.3D-E), which eliminate one glycine motif within the zipper, exhibit
fibril morphology but lack the typical lateral association observed with the WT.
5.3.3 Glycine zipper mutations reduce hydrodynamic radii
Aggregation end products were assessed for their effect on aggregate size using
hydrodynamic radii (RH) measurements from DLS. Preliminary results, shown in
Figure 5.4, indicate that three samples, L17G A21G, G25A, and G25I, were smaller than
the WT by approximately 50%. Mutations that reduced the length of the glycine zipper
created the smallest aggregates with RH of 75-100 nm, while mutations that increased the
zipper produced aggregates between 100-125 nm. Additionally, L17G A21G aggregates
are slightly smaller than V18G E22G, and G25A is slightly smaller than G25I.
5.3.4 Glycine zipper mutations have no impact on conformation
End products of aggregation were assessed for conformational changes using ANS,
a dye that binds to hydrophobic residues on the surface of aggregates, as shown in
Figure 5.5. Aggregates were diluted into a 50-fold excess of ANS, and fluorescence was
measured and integrated from 450-550 nm. Preliminary results demonstrate that the
extension of the motif (L17G A21G, V18G E22G), creates aggregates roughly the same
hydrophobicity as the WT, while G25I and G25A, mutations that reduce the motif, slightly
reduce hydrophobicity.
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5.3.5 Extension of the glycine motif increases the quantity of soluble aggregates
Aggregates were injected onto an AKTA FPLC with an attached column of
Superdex 75 prep grade resin. Using in-line UV, the absorbance spectra was reported as
shown in Figure 5.6. Insoluble aggregates were removed using a filter at the top of the
column. Preliminary results indicate that when the glycine motif was extended (L17G
A21G and V18G E22G) more soluble aggregates were formed, evidenced by increase
protein elution within the void peak (10 mL). However, when the glycine motif was
attenuated (G25A and G25I), a reduction in the relative quantity of soluble aggregates was
observed. Additionally, a shifted monomer peak appears in the L17G A21G and G25A
samples.
5.4 Discussion
Glycine zippers are an important structural motif. Responsible for packing and
folding within the leaflets of TMP, glycine zippers also are theorized to play a role in
amyloid protein aggregation. One such TMP is APP, the protein that is cleaved to form
Aβ, the protein associated with AD. Embedded within the APP sequence is a repeated chain
of GxxxG, the so-called glycine zipper, much of which is located within the region cleaved
to form Aβ. This study investigates four different modifications to the glycine zipper region
within Aβ. L17G A21G and V18G E22G, mutations modeled after naturally occurring and
particularly pathogenic familial AD mutations, were selected for their ability to increase
the zipper motif. G25A and G25I, in contrast, were selected for their ability to attenuate
with the motif with varying degrees of bulk. Mutations were assessed for effects on
aggregation kinetics, morphology, size, and surface hydrophobicity. Results indicate that
L17G A21G and V18G E22G, extensions of the motif, rapidly create aggregates that are
70

smaller than the WT, while attenuation of the motif, G25A and G25I, create aggregates
that are more similar to the WT.
Mutations were initially tested for their ability to affect aggregation. Results, shown
in Figure 5.2, indicate that mutations have a significant effect on aggregation. However,
the kinetic model still fails to capture the peaks for several mutations (V18G E22G and
G25A). Based on the fluorescent data, it appears mutations have a modest effect on lag
phase for the growth, with L17G A21G and V18G E22G shortening the lag period while
G25A slightly extends it. Additionally, only one mutation, L17G A21G, has a consistent
effect on the extent of aggregation. Additional model optimization and data will shed more
light on the true kinetic effects of these mutations.
These results are not unexpected. Previous studies have examined the effects of
A21G and E22G, two familial AD mutations commonly referred to as the Flemish and
Arctic variant, respectively. These mutations are associated with particularly pathogenic
strains of AD [23]. A21G and E22G also alter aggregation kinetics [143,145]; similar to
our results, studies have shown that these mutations very rapidly aggregate [146].
Our preliminary results also align favorably with the observed behavior of
mutations after equilibrium is reached [147]. Previous work examining any double
mutations within Ab has shown their propensity to aggregate to a metastable state before
decline to a secondary more stable plateau [146]. Norlin et al observed the changes in
aggregation plateau with the E22G and were able to correlate it with aggregate clumping
as part of fibril formation. This pattern is also observed with other single mutations
effecting the Aβ salt bridge region near E22 [148]. Where our mutation was at the Nterminal end of the motif, some studies have probed the elimination of internal glycines in
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the zipper motif to reveal that elimination of one internal glycine hindered the formation
of aggregates and reduced the quantity of aggregates formed [139,140,149].
Previous works have also associated extensions in the glycine zipper with altered
conformations. Rodziewicz-Motowidlo et. al attributed this observation to a change in
helix formation during early aggregation: E22G forms a more well defined 310 helix, while
WT forms a more stable a-helix [150]. While our work showed largely similar
hydrophobic conformations when looking at ANS spectroscopy (Figure 5.5), this was by
no means an exhaustive examination of structure, and it is possible that changes in
hydrophobicity are due to the structural change and not a physical conformational shift.
Indeed, in our own study, aggregate morphology was significantly altered as
observed in TEM images, Figure 5.3, implying there are more structural changes than
characterized by ANS alone. While zipper extensions resulted in an increase in soluble
aggregates, they also created smaller aggregates. Similar to the familial AD mutants
Poduslo and Howell investigated, aggregates were short and non-fibrillar [151]. However,
it is possible this morphology arises because the aggregates had not reached their final fibril
structure and were merely clumping, as observed by Norlin [146]. While the effects of an
extended motif were remarkable, mutations attenuating the motif (G25I, G25A) created
aggregates similar in morphology to the WT. Additionally, analysis of TEM images of
aggregation end products (Figure 5.3) revealed a vastly changed morphology. Further
characterization such as CD or NMR would shed more light on conformational changes.
In addition to a change in aggregate morphology, our results also show a reduction
in aggregate hydrodynamic radius (Figure 5.4). Across the board, all four mutations
reduced the hydrodynamic radius of aggregates formed. Similarly, Harmeier et al
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previously targeted G33 and simultaneously decreased the appearance of large aggregates
and increased the amount of smaller aggregates [149]. While our work only showed an
increase in the amount of soluble aggregates for L17G A21G and V18G E22G (Figure 5.6),
it is possible that G25A and G25I were forming insoluble species which were subsequently
filtered out. Interestingly, while Aβ aggregation typically retains a large portion of
monomer during aggregation [148], monomer peaks were only observable for two variants:
L17G A21G and G25A, and the latter exhibited a shifted peak (Figure 5.6).
While much work remains to fully understand their function, glycine zippers play
an important role in amyloid aggregation. Our results indicate that extension of the glycine
zipper both promotes aggregation and alters aggregate structure. L17G A21G and V18G
E22G, two mutations which extended the zipper motif, rapidly aggregated and formed
aggregates that were smaller in size than the WT. In contrast, G25A and G25I, which
attenuated the zipper motif, delayed the onset of aggregate formation and created more
prototypical aggregates: their morphology was largely similar to that of the WT albeit much
thinner and with a reduced hydrophobicity. Ultimately, these results indicate that
aggregation is significantly influenced by the remnants of the APP glycine zipper.
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Figure 5.1. Glycine zipper mutations. Amyloid mutants were designed for their ability
to increase (L17G A21G, V18G E22G) or decrease (G25A, G25I) the glycine zipper motif
(black boxes) in the WT Aβ sequence. Mutants that increase the motif are either a direct
extension (L17G A21G) or an extension shifted by 1 unit (V18G E22G). Both extensions
pass through the hydrophobic core (black line). Mutants that decrease the sequence use
either a bulky (G25I) or constrained substitution (G25A) (grey box).
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Figure 5.2. Glycine zipper mutations alter aggregation kinetics. Aβ monomer were
aggregated in the presence of NaCl and thioflavin t, a dye that exhibits enhanced
fluorescence in the presence of β-sheet structure. Preliminary data for Aβ WT (Panel A,
¡) and mutants L17G A21G (Panel B, r), V18G E22G (Panel C, ¯) and G25A (Panel
D, £) are shown relative to their fits to a kinetic model (solid lines).
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Figure 5.3. Changes to the glycine zipper alter aggregate morphology. Aggregation
end products were negatively stained and imaged using TEM. Mutations were compared
against the WT (panel A), that either increased the glycine motif, L17G A21G (panel B)
and V18G E22G (panel C), resulted in smaller more truncated aggregates. Images are
representative of 2-3 independent experiments.
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Figure 5.4. Glycine motif changes reduce aggregate hydrodynamic radii. Following
aggregation, hydrodynamic radii (RH) were measured using light scattering. Error bars
indicate mean ± SEM, n=1-3.
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Figure 5.5. Glycine zipper changes have a slight effect on conformation. Aggregation
end products were diluted with ANS, a dye that exhibits enhanced fluorescence in the
presence of hydrophobic residues and measured for fluorescence was measured at
excitation 350 nm, emission 400-600 nm. Results were calculated using the integrated area
under the curve from 450 – 550 nm. Error bars indicate mean ± SEM, n=1-3.
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Figure 5.6. Soluble aggregates are effected by glycine zipper mutations. Aggregation
end products were fractionated using SEC on Superdex 75 with in-line UV absorbance
readings. Curves are representative of 1-2 independent experiments
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CHAPTER 6
CONCLUSIONS
With the projected global growth in AD over the next few decades [152], continued
research into treatment methods is vital. While many of the current treatments have evolved
from targeting the symptoms, epidemiological studies have revealed equally promising
target [116,153]. This study evaluated the effect of two classes of naturally occurring
compounds: olive-derived phenylethanoids and soy isoflavones. These compounds were
examined for their ability to modulate Aβ-induced toxicity through either anti-aggregation
or antioxidant effects. In addition to modulating aggregation through naturally occurring
compounds, this study also looked at the role of the internal amyloid glycine zipper.
Through the use of glycine zipper mutants, the effect of zipper extension or reduction was
examined for its effects on Aβ aggregate biophysical characteristics.
Chapter 3 explored the ability of olive-derived phenylethanoids to modulate Aβ. A
vital part of the Mediterranean diet, phenylethanoids oleuropein (OLE), hydroxytyrosol
(TOH), and tyrosol (TYR) were examined for their ability to modulate aggregation,
oligomerization, morphology, and changes to Aβ-induced caspase activation. While no
compound had an observed impact on morphology, OLE effected monomer aggregation
by increasing the relative extent of aggregation. All three phenylethanoids reduced the
amount of monomer and shifted aggregate equilibrium towards larger aggregates. While
these results were interesting, they did not translate to a reduction in Aβ-induced caspase
activation.
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The study went further to look at both antioxidant capacity and its effect on toxicity,
revealing all phenylethanoids were good antioxidants. While this effect had a slight but
insignificant effect on toxicity directly, antioxidant capacity correlated strongly with their
ability to attenuate oligomer-induced toxicity. While these mechanisms were ineffective at
reducing toxicity separately, the combined effect was remarkable: all phenylethanoids were
able to reduce toxicity by 80%. More interestingly, TYR, the phenylethanoid that had an
antioxidant merely equivalent to Trolox, had the greater reduction in toxicity. This
indicates a multi-target effect between the two mechanisms.
Chapter 4 examined the ability of genistin (OGEN), genistein (GEN), daidzin
(ODEN), and daidzein (DEN), four soy-derived isoflavones (SIFs), to alter Aβ-associated
toxicity and attempt to ascertain the mechanism. Initial results showed that all four SIFs
were able to reduce oligomer toxicity when acting concurrently through anti-aggregation
effects and antioxidant effects. Interestingly, there was a significant reduction in
effectiveness when the 5 hydroxyl on OGEN and GEN was removed to create ODEN and
DEN, respectively. No effect was observed with the addition of a glucose. We then
assessed the anti-aggregation effects directly. Here, the presence of a glucose (OGEN and
ODEN) significantly increased the extent of aggregation compared to the aglycones (GEN
and DEN). And, while all four SIFs tested had a significant effect on the lag time to
aggregate formation, only three of the SIFs (OGEN, GEN, and DEN) had an effect on
aggregation rate. SIFs had minimal effect on Aβ oligomer size and distribution and no
effect on conformation. Ultimately these anti-aggregation effects alone had no effect on
toxicity.
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Next, the effect of SIFs on antioxidant processes was examined. Previous studies
have shown many SIF properties are directly attributable to their antioxidant capacity.
Indeed, our results indicate that all four SIFs are good antioxidants and OGEN and GEN
are significantly better than Trolox. Additionally, some their effectiveness could be due to
their effect on intracellular processes, such as catalase. Results indicate that three of the
SIFs, GEN, ODEN, and DEN, increased catalase activity. Unfortunately, only DEN had a
significant effect on oligomer-toxicity.
To explain the reduction observed with OGEN, GEN, and ODEN, we looked at the
relative effect of each process and combined them. This revealed that each SIF acted in a
different manner: ODEN acted equally through both its anti-aggregation effects and by
upregulating intracellular processes. OGEN had a clear additive effect between the two
mechanisms. DEN acted through antioxidant processes. Most interestingly, GEN exhibited
synergy between the two mechanisms, a result our group has previously observed for
kampferol, a structurally related polyphenol.
Finally, Chapter 5 explored the role of the glycine zipper in Aβ aggregation through
the use of selective mutations. Mutations were selected that either extended (L17G A21G,
V18G E22G) or attenuated (G25A, G25I) the embedded Aβ glycine zipper motif.
L17G A21G and V18G E22G were selected because of their similarity to two familial AD
mutations: the Flemish and Arctic, respectively. G25A and G25I were selected to replace
the glycine with a relatively similar or much larger amino acid to assess the importance of
residue G25 on aggregation. Preliminary results indicate extension of the motif speeds
aggregate formation, creating aggregates that are morphologically smaller than the WT and
that begin to aggregate very rapidly. While the lag phase for the WT is many hours, these
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mutants begin to aggregate in less than an hour. Conversely, mutations which eliminate
one glycine in the sequence result in aggregates that have both a similar lag time and
morphology to the WT. While the G25A and G25I variants formed a familiar mesh network
like the WT, they were much thinner than WT fibrils.
Studies to assess the conformation using ANS showed that both G25A and G25I
had less exposed hydrophobic surfaces, while the other mutants were very similar to the
WT. DLS studies revealed that all changes to the glycine zipper resulted in aggregates that
exhibited a smaller hydrodynamic radius than the WT. Finally, size exclusion
chromatography was used to assess the relative quantity of soluble aggregates formed.
Results indicated that when the motif was extended (L17G A21G, V18G E22G) more
soluble aggregates were formed while an attenuation (G25A, G25I) of the motif resulted
in fewer soluble aggregates. This trend is likely due to the more typical fibril structure
formed by the attenuated motif mutants.
Ultimately, this study successfully identified three ways to modulate Aβ
aggregation. Phenylethanoids are able to simultaneously act through anti-aggregation and
antioxidant mechanisms to attenuate toxicity. Similarly, soy isoflavones are able to act
through a variety of pathways to attenuate the effects of Aβ. And, finally, the glycine zipper
is very important for amyloid formation.
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CHAPTER 7
FUTURE PERSPECTIVES
There are numerous avenues to continue this work. Previous studies with
phenylethanoids, for example, have shown the ability to alter the conformation of specific
aggregates and create non-toxic variants. It would be beneficial to explore our own
oligomers in a similar manner: isolate various species and sizes of oligomers and
biophysically characterize the specific effects on each region. It would also be helpful to
investigate other potential intracellular processes stimulated by polyphenols. This study
only began to examine potential mechanisms. While they are all very good antioxidants,
the work with the SIFs show that there are likely other mechanisms modified by
phenylethanoids. A viable route forward would be to analyze gene regulation, RNA, or
even the associated downstream protein extracts to probe whether relative expression is
altered by any of the treatments.
Finally, SIFs should be explored for their exact mechanisms. While this work
shows that the several SIFs are upregulating catalase, not all of them did. Previous studies
with GEN show that it is able to upregulate a variety of intracellular processes. It is
necessary to fully explore the pathways to examine their effects on toxicity. And,
considering the previous studies that have shown transcriptional effects from SIFs, this
would be a good place to start. Both phenylethanoids and SIFs would also benefit from an
examination of specific caspase markers. While our assay probes a broad overview of
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caspases, it would be most beneficial from a clinical perspective to isolate specific modes
of action for the modulators.
While additional studies would be beneficial, there are also other compounds, both
phenylethanoid and SIF, to assess for their anti-aggregation effects. This study was by no
means exhaustive in its assessment of phenylethanoids or SIFs: it looked at a limited subset
set of 3 phenylethanoids and soy 4 soy isoflavones, choosing the most common of the two
groups. However, the encouraging results presented here motivate the exploration of other
compounds such as oleocanthal (phenylethanoid) and glycitein (SIF) that warrant further
exploration.
Finally, further studies with glycine zippers should focus on their interaction
between aggregates and cells. This includes both in vitro effects to examine their toxicity
as well as utilizing artificial constructs with lipid bilayers to examine pore formation. While
the current work examines several possible mutations, the next series of changes should
expand to other glycines in the zipper sequence, perhaps focusing on the intermediate
glycines to learn whether similar effects are observed.
Additionally, more work is needed to fully optimize the kinetic model. While it is
effective in samples with more traditional growth and decay phases, edge cases, such as
ones with very large or very small rate constants or samples with a delayed decay phase
remain troublesome. Instead of using the average values for a trial to fit, it would be more
representative to take the average of kinetic parameters. Additionally, larger sample sizes
will help. Our sample size is limited to 2-3 trials for each of the mutations and WT. A
more robust number of trials will help to remove outliers.
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APPENDIX A
CELL INTERPRETOR CODE
The following script was written by Nick van der Munnik to identify and count
cells using the Hoescht (blue) channel and apoptotic cells using the FLICA ™ (green)
channel and quantify the relative amount of caspase active cells. To perform this, it also
calls the “GHOSTCELLS2.m” function which is described in Appendix B.
% SPECIFY THE NUMBER OF SAMPLES YOU WISH TO PROCESS
NUMSAM=55;
DAPI=[];
FITC=[];
FIG=[];
DATAOUTPUT=ZEROS(NUMSAM,3);
INDEX=ZEROS(NUMSAM,1);
TIC;
I=1;
WHILE I<=9 && I<=NUMSAM
DAPI=UINT8(IMREAD(STRCAT('DAPI00',NUM2STR(I),'.JPG')));
FITC=UINT8(IMREAD(STRCAT('FITC00',NUM2STR(I),'.JPG')));
[DATAOUTPUT(I,:),FIG]=GHOSTCELLS2(DAPI,FITC);
INDEX(I,1)=I;
IMWRITE(FIG,STRCAT('MLIMAGE',NUM2STR(I),'.TIF'));
FIGURE
IMSHOW(FIG)
I=I+1;
END
WHILE I>9 && I<=NUMSAM
DAPI=UINT8(IMREAD(STRCAT('DAPI0',NUM2STR(I),'.JPG')));
FITC=UINT8(IMREAD(STRCAT('FITC0',NUM2STR(I),'.JPG')));
[DATAOUTPUT(I,:),FIG]=GHOSTCELLS2(DAPI,FITC);
INDEX(I,1)=I;
IMWRITE(FIG,STRCAT('MLIMAGE',NUM2STR(I),'.TIF'));
FIGURE
IMSHOW(FIG)
I=I+1;
END
100

FPRINTF('AVERAGE TIME PER SAMPLE (MINUTES)')
TOC/(60*NUMSAM)
FPRINTF(' INDEX CELLS DEAD_CELLS TUNEL/DAPI')
DATAOUTPUT=[INDEX DATAOUTPUT
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APPENDIX B
CELL COUNT PROGRAM
FUNCTION [DATA,OUTPUT]=GHOSTCELLS2(D,F)
P=D(:,:,3);
% USES BLUE CHANNEL FOR DAPI
FIT=F(:,:,2);
% USES GREEN CHANNEL FOR FITC
DIM=SIZE(P);
RDIM=DIM(1,1);
CDIM=DIM(1,2);
DTHRESH=5;
CRAD=50;

% LIVE/DEAD THRESHOLD
% RADIUS OF CELL

MINCON=38;
MINEX=40;
MAXCON=130;
NSTEPS=5;
PSTORE=P;
CELLS=0;
DEADCELLS=0;
Q=P*0;
S=P*0;
OUTPUTF=P*0;
OUTPUTD=P*0;
LTAG=P*0;
DTAG=P*0;
RTAG=P*0;
OUTPUT=ZEROS(RDIM*2,CDIM);
BIN=P*0;
NEGATIVE=P*0;
CIDRINIT=ZEROS(1000,1);
CIDCINIT=ZEROS(1000,1);
%COUNT CELLS
FOR STEP=0:NSTEPS
THRESH=110-STEP*(100/NSTEPS);
P=PSTORE;
%MAKE BLACK/WHITE
FOR I = 1:RDIM
FOR J = 1:CDIM
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IF P(I,J) >= THRESH
P(I,J) = 100;
ELSE
P(I,J) = 0;
END
IF STEP==NSTEPS
IF P(I,J) >= THRESH
BIN(I,J) = 1;
NEGATIVE(I,J)=0;
ELSE
BIN(I,J) = 0;
NEGATIVE(I,J)=100;
END
END
END
END
%OUTLINE CELLS
FOR I = 2:RDIM-1
FOR J = 2:CDIM-1
IF P(I,J) ==100
IF P(I-1,J)==0 && P(I+1,J)==100
P(I,J)=200;
ELSEIF P(I-1,J)==100 && P(I+1,J)==0
P(I,J)=200;
ELSEIF P(I,J-1)==0 && P(I,J+1)==100
P(I,J)=200;
ELSEIF P(I,J-1)==100 && P(I,J+1)==0
P(I,J)=200;
END
END
END
END
P(1,:)=200;
P(:,1)=200;
P(RDIM,:)=200;
P(:,CDIM)=200;
%SQUEEZE CELL OUTLINES BY HALF MINIMUM FEATURE SIZE
FOR K=0:(MINCON/2)
FOR I = 2:RDIM-1
FOR J = 2:CDIM-1
IF P(I,J)==100
IF P(I-1,J)==200+K && P(I+1,J)==100
P(I,J)=200+K+1;
ELSEIF P(I-1,J)==100 && P(I+1,J)==200+K
P(I,J)=200+K+1;
ELSEIF P(I,J-1)==200+K && P(I,J+1)==100
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P(I,J)=200+K+1;
ELSEIF P(I,J-1)==100 && P(I,J+1)==200+K
P(I,J)=200+K+1;
ELSEIF P(I-1,J)>=200 && P(I+1,J)>=200
P(I,J)=200+K+1;
ELSEIF P(I,J-1)>=200 && P(I,J+1)>=200
P(I,J)=200+K+1;
END
END
END
END
%
IF(STEP==NSTEPS)
%
FIGURE
%
IMSHOW(P)
%
END
END
FOR I = 1:RDIM
FOR J = 1:CDIM
IF P(I,J) >= 200
P(I,J) = 200;
END
END
END
FOR I = 2:RDIM-1
FOR J = 2:CDIM-1
IF P(I,J) ==100
IF P(I-1,J)==200 && P(I+1,J)==200
P(I,J)=200;
ELSEIF P(I,J-1)==200 && P(I,J+1)==200
P(I,J)=200;
END
END
END
END
P=P-Q;
FOR K=0:(MAXCON-MINCON)/2
%TEST FOR CONVERGENCE, EXCLUDE AREA AROUND CONFIRMED
CELL
FOR I = (MINCON/2):RDIM-(MINCON/2)
FOR J = (MINCON/2):CDIM-(MINCON/2)
IF P(I,J) ==100
INDEX=0;
IF P(I-2,J)>=200 && P(I+2,J)>=200
IF P(I,J-2)>=200 && P(I,J+2)>=200
INDEX=1;
END
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END
IF P(I-2,J-1)>=200 && P(I+2,J-1)>=200
IF P(I+1,J-2)>=200 && P(I+1,J+2)>=200
INDEX=INDEX+1;
END
END
IF P(I-1,J-2)>=200 && P(I-1,J+2)>=200
IF P(I-2,J+1)>=200 && P(I+2,J+1)>=200
INDEX=INDEX+1;
END
END
IF INDEX==3
IF P(I-2,J-2)>=200 && P(I+2,J-2)>=200
IF P(I-2,J+2)>=200 && P(I+2,J+2)>=200
CELLS = CELLS+1;
FOR M = -MINEX:MINEX;
FOR N = -MINEX:MINEX;
IF SQRT(M^2+N^2)<=MINEX
IF I-M>=1 && I-M<=RDIM
IF J-N>=1 && J-N<=CDIM
Q(I-M,J-N)=1000;
P(I-M,J-N)=-1000;
END
END
END
END
END
CIDRINIT(CELLS)=I;
CIDCINIT(CELLS)=J;
S(I,J)=1000;
FOR M = 0:9;
FOR N = 0:9;
LTAG(I-4+M,J-4+N)=1000;
END
END
END
END
END
END
END
END
%CONTINUE TO SQUEEZE
FOR I = 2:RDIM-1
FOR J = 2:CDIM-1
IF P(I,J)==100
IF P(I-1,J)==200+K && P(I+1,J)==100
105

P(I,J)=200+K+1;
ELSEIF P(I-1,J)==100 && P(I+1,J)==200+K
P(I,J)=200+K+1;
ELSEIF P(I,J-1)==200+K && P(I,J+1)==100
P(I,J)=200+K+1;
ELSEIF P(I,J-1)==100 && P(I,J+1)==200+K
P(I,J)=200+K+1;
ELSEIF P(I-1,J)==200+(K+1) && P(I+1,J)==200+K
P(I,J)=200+K+1;
ELSEIF P(I-1,J)==200+K && P(I+1,J)==200+(K+1)
P(I,J)=200+K+1;
ELSEIF P(I,J-1)==200+(K+1) && P(I,J+1)==200+K
P(I,J)=200+K+1;
ELSEIF P(I,J-1)==200+K && P(I,J+1)==200+(K+1)
P(I,J)=200+K+1;
END
END
END
END
END
END
%SEGMENT CELL CLUSTERS
PC=IMCOMPLEMENT(PSTORE);
PMIN=IMIMPOSEMIN(PC,~BIN|S);
P=WATERSHED(PMIN);
P=UINT8(P);
FOR I = 1:RDIM
FOR J = 1:CDIM
IF P(I,J) >0
P(I,J) = 100;
ELSE
P(I,J) = 0;
END
END
END
OUTPUTF=(P/100).*FIT;
OUTPUTD=(P/100).*PSTORE;
%COUNT DEADCELLS
CVEC=ZEROS(CELLS,1);
CIDR=CVEC;
CIDC=CVEC;
FOR I=1:CELLS
CIDR(I,1)=CIDRINIT(I,1);
CIDC(I,1)=CIDCINIT(I,1);
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END
FOR C=1:CELLS
I=CIDR(C,1);
J=CIDC(C,1);
FITCSUM=UINT32(0);
CMOVES=0;
FOR M=-CRAD:CRAD
FOR N=-CRAD:CRAD
IF I+M>1 && I+M<RDIM && J+N>1 && J+N<CDIM
IF SQRT(M^2+N^2)<=CRAD
CMOVES=CMOVES+1;
FITCSUM=FITCSUM+UINT32(FIT(I+M,J+N));
IF SQRT(M^2+N^2)>CRAD-1
RTAG(I+M,J+N)=112;
END
END
END
END
END
IF DOUBLE(FITCSUM/CMOVES)>=DTHRESH
DEADCELLS=DEADCELLS+1;
FOR M = -2:2;
FOR N = -2:2;
DTAG(I+M,J+N)=1000;
END
END
END
END
OUTPUTF=OUTPUTF+LTAG+RTAG-DTAG;
OUTPUTD=OUTPUTD+LTAG-DTAG;
OUTPUT=[OUTPUTF OUTPUTD];
DATA=ZEROS(1,3);
DATA(1,1)=CELLS;
DATA(1,2)=DEADCELLS;
DATA(1,3)= DEADCELLS/CELLS;
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APPENDIX C
COINCIDING IMAGE FOR CHAPTER 3

Figure C.1. Aβ oligomers induce caspase activity for phenylethanoid experiments.
SH-SY5Y human neuroblastoma cells were treated with either buffer alone (VEH), a 10
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nM Aβ1-42 oligomer preparation (Aβ), or 1.5 U TNF-⍺ (TNF-⍺). A) Following a 24-h
incubation, cells were stained for nuclear markers (Hoescht 33342, blue) and activated
caspases (FLICA™, green) and imaged as described in Figure 4. Images are shown relative
to a scale bar of 10 µm and are representative of 9-15 independent experiments. B) Images
were quantified as in Figure 4, and the percentage of caspase active cells is reported. Error
bars indicate SEM, n=9-15. **p<0.01, ***p<0.001 versus VEH
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APPENDIX D
COINCIDING IMAGES FOR CHAPTER 4

Figure D.1. SIF-induced Aβ oligomers conformational changes. Aβ oligomers were
diluted in a 50-fold excess of ANS and fluorescence was measured from 400-600 nm black
line). For each sample, curves were integrated from 450-550
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Figure D.2. SIFs reduce Aβ oligomer toxicity when acting through multiple
mechanisms. SH-SY5Y human neuroblastoma cells were treated with 10,000 nM SIF and
10 nM oligomers formed in the presence of a 10-fold excess of SIF. Following 24-h
incubation, cells were stained for nuclear markers (Hoescht 33342, blue) and activated
caspases (FLICA™, green), imaged, and quantified as described in Figure 4. Images are
representative of 3-4 independent experiments. Scale bar = 10 µm.
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Figure D.3. SIFs have no anti-aggregation effect on Aβ oligomers induced caspase
activity. SH-SY5Y human neuroblastoma cells were treated with 10 nM oligomer
formed in the presence of 100 nM SIF. Following 24-h incubation, cells were stained for
nuclear markers (Hoescht 33342, blue) and activated caspases (FLICA™, green),
imaged, and quantified as described in Figure 4. Images are representative of 3-4
independent experiments. Scale bar = 10 µm.
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Figure D.4. Antioxidant effect of SIFs on Aβ oligomers induce caspase activity.
SH-SY5Y human neuroblastoma cells were treated with 10,000 nM SIF and 10 nM
oligomer formed in the absence of SIF. Following 24-h incubation, cells were stained for
nuclear markers (Hoescht 33342, blue) and activated caspases (FLICA™, green), imaged,
and quantified as described in Figure 4. Images are representative of 3-4 independent
experiments. Scale bar = 10 µm.
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Figure D.5. Aβ upregulates caspase activity. SH-SY5Y human neuroblastoma cells were
treated with either vehicle (VEH), 10 nM Aβ oligomers (Aβ), or 1.5 U TNF⍺ (TNF⍺). A)
Following 24-h incubation, cells were stained for nuclear markers (Hoescht 33342, blue)
and activated caspases (FLICA™, green), imaged, and quantified as described in Figure 4.
Images are representative of 15 independent experiments. B) The percentage of caspase
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active cells is reported relative to the control, represented by a dashed line at 1. Error bars
indicate SEM, n=15. **p<0.01, ***p<0.001 versus control.
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